FORM 10-K Annual Report

0001078782-12-001613.txt : 20120612 0001078782-12-001613.hdr.sgml : 20120612 20120612130536 ACCESSION NUMBER: 0001078782-12-001613 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20120229 FILED AS OF DATE: 20120612 DATE AS OF CHANGE: 20120612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PHARMA INVESTING NEWS, INC. CENTRAL INDEX KEY: 0001520047 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 320337695 STATE OF INCORPORATION: NV FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 333-174271 FILM NUMBER: 12902426 BUSINESS ADDRESS: STREET 1: 1810 EAST SAHARA AVE STREET 2: SUITE 1571 CITY: LAS VEGAS STATE: NV ZIP: 89104 BUSINESS PHONE: 702-664-6555 MAIL ADDRESS: STREET 1: 1810 EAST SAHARA AVE STREET 2: SUITE 1571 CITY: LAS VEGAS STATE: NV ZIP: 89104 10-K 1 f10k022912_10k.htm FORM 10-K ANNUAL REPORT FORM 10-K Annual Report

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

X .

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended February 29, 2012

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from ________ to ______

PHARMA INVESTING NEWS, INC.

[f10k022912_10k002.gif]

(Exact name of registrant as specified in its charter)


Nevada	333-174271	32-0337695
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification Number)

	1810 East Sahara Ave Suite 1571 Las Vegas, NV 89104 (Address of principal executive offices)

	(702) 664-6555
	(Registrant’s Telephone Number)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes . No X .

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes . No X .

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.

Yes X . No .

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

(Not required) Yes X . No .

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. .

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.


Large accelerated filer	.	Accelerated filer	.
Non-accelerated filer	. (Do not check if a smaller reporting company)	Smaller reporting company	X .

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes . No X .

The aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant as of February 29, 2012 was $nil based upon the price ($nil) at which the common stock was last sold as of the last business day of the most recently completed second fiscal quarter, multiplied by the approximate number of shares of common stock held by persons other than executive officers, directors and five percent stockholders of the registrant without conceding that any such person is an “affiliate” of the registrant for purposes of the federal securities laws.

As of June 6, 2012, there were 5,361,015 shares of the registrant’s $0.001 par value common stock issued and outstanding.

Documents incorporated by reference: None

Table of Contents


		Page
	PART I

Item 1	Business	4
Item 1A	Risk Factors	9
Item 1B	Unresolved Staff Comments	9
Item 2	Properties	9
Item 3	Legal Proceedings	9
Item 4	Mine Safety Disclosures	9

	PART II

Item 5	Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	10
Item 6	Selected Financial Data	10
Item 7	Management's Discussion and Analysis of Financial Condition and Results of Operations	10
Item 7A	Quantitative and Qualitative Disclosures about Market Risk	12
Item 8	Financial Statements and Supplementary Data	F-1
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	13
Item 9A	Controls and Procedures	13
Item 9B	Other Information	14

	PART III

Item 10	Directors and Executive Officers and Corporate Governance	15
Item 11	Executive Compensation	17
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	18
Item 13	Certain Relationships and Related Transactions	19
Item 14	Principal Accountant Fees and Services	20

	PART IV

Item 15	Exhibits	21

FORWARD-LOOKING STATEMENTS

The availability and adequacy of our cash flow to meet our requirements;

Economic, competitive, demographic, business and other conditions in our local and regional markets;

Changes or developments in laws, regulations or taxes in our industry;

Actions taken or omitted to be taken by third parties including our suppliers and competitors, as well as legislative, regulatory, judicial and other governmental authorities;

Competition in our industry;

The loss of or failure to obtain any license or permit necessary or desirable in the operation of our business;

Changes in our business strategy, capital improvements or development plans;

The availability of additional capital to support capital improvements and development; and

Other risks identified in this report and in our other filings with the Securities and Exchange Commission or the SEC.

This report should be read completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Use of Term

Except as otherwise indicated by the context, references in this report to “Company”, “PHIN”, “we”, “us” and “our” are references to Pharma Investing News, Inc. All references to “USD” or United States Dollars refer to the legal currency of the United States of America.

PART I

ITEM 1.

BUSINESS

Overview

Pharma Investing News, Inc. was incorporated in the State of Nevada on February 8, 2011. However, we commenced initial operations in July 2008 with the registration of our website domain pharmainvestingnews.com. These initial operations consisted of developing the website and establishing our marketing plan. We officially launched pharmainvestingnews.com in late 2008. Since that time, until we incorporated in 2011, we had been operating as an unincorporated entity, solely owned by our founder, Mr. Robert Lawrence. Our corporate headquarters are located in Las Vegas, Nevada, and our telephone number is (702) 664-6555.

Pharma Investing News, Inc. is an internet-based company that provides advertising solutions to pharmaceutical and biotechnology companies. The goal of pharmainvestingnews.com is to provide an online community where pharmaceutical and biotechnology companies will be able to provide corporate updates and other information to the public. This service is free of charge to viewers and offers pharmaceutical and biotech companies the ability to showcase their businesses and build brand awareness. We intend to establish our website as a valuable resource for the pharmaceutical and biotechnology industries where the public will go to find the latest information relating to the industry, as a whole, as well as specific information about companies and new product details. We believe that we can position pharmainvestingnews.com to become an all-inclusive resource, allowing users to acquire in-depth analyses, detailed marketing information and current news on research and development and other trends within the pharmaceutical and biotech industries.

In order to set ourselves apart and establish pharmainvestingnews.com as the online resource for the latest news and developments in the pharmaceutical and biotechnology sectors, we believe that we have developed a business model that will allow the Company to generate revenue while offering a valuable service to both individuals and the industry alike. For our current clients we assist in the development and management of marketing campaigns that are launched on pharmainvestingnews.com and other outlets across the internet. Our specifically designed marketing campaigns utilize, not only pharmainvestingnews.com, but we also offer a suite of services that allow our clients to take advantage of other online media channels. These marketing campaigns are designed to assist our clients with the promotion of their goods and services directly to the public. The goal of our advertising is to create brand awareness, not only for our clients, but for pharmainvestingnews.com. By establishing pharmainvestingnews.com as a trusted online resource we will be able to maximize our revenue while providing a service that benefits both the public and the pharmaceutical and biotechnology sectors alike.

Products and Services

Through our current website and anticipated future enhancements, it is our goal to provide both our clients and our viewers with a website with multi-level functionality that enables clients to showcase their businesses while enabling viewers to receive up-to-date information relating to our client’s current product offerings and general corporate updates, including our client’s performance in the capital markets.

PharmaInvestingNews.com for Clients

Since the creation of our business plan and the initial development of our website, it has been our goal to provide our clients with more than just a venue for static ad placements. It is our goal to provide our clients with multi-level advertising solutions in which they are able to showcase all facets of their company. We offer different marketing packages based on our client’s needs and advertising needs and timeframes. The marketing campaigns that we’ve designed are offered in 3, 6 and 12 month terms, and we will enter into written agreements with clients who decide to use our services. Our pricing for our currently offered packages is as follows:

3 Months- $ 8,000

6 Months- $13,000

12 Months- $21,000

We currently offer the following services as part of our packages:

Homepage Features – As with most websites, the homepage of our website is the most viewed page; thus, all of our clients are listed on the homepage of our website. We also offer featured advertising spots on our homepage so that our clients, for an additional fee, may gain maximum exposure to potential viewers. We can track click-through ratios to prove to our clients that featured advertising spots on our homepage lead to more profile page (discussed below) views for our client’s respective company.

Profile Pages – Profile pages make up the bulk of our website. Profile pages allow clients to showcase information about their company. Each of our advertising clients has a profile page to feature information such as: corporate history, product and research developments, news and events, featured articles, and stock information.

Corporate Video Production – We also offer corporate video production for our clients. We can then upload the video to our website to further market our clients. We can also provide our clients with a hard-copy of their video.

Ad-Stopper – Our most inclusive marketing package includes two uses of an ad-stopper, whereby the website will only run that particular Company’s advertisements for a full day.

Additional Services

We offer the following additional services as add-ons to our packages, but prices vary depending on the service provided:

Radio and Video Interviews – As with our video production capabilities, we can also create radio and video interviews for our clients. We will interview clients in a question and answer format, based on material that the client would like to discuss and highlight. These interviews are then prepared for integration onto our website and/or given to the client for their use. Price is dependent on the time of year, air time, and interviewer used.

Social Media Campaigns – Social media, including Facebook, Twitter, Myspace, etc. is a growing marketing venue. We feel that it is necessary for our clients to develop a social media presence, so we offer our clients full social media campaigns in which we will manage all of their accounts. All- inclusive social media campaigns on a monthly basis are $1100 per month; however, if we have a client that signs up for 6 months we offer a 10% discount and for 12 months we offer a 15% discount.

Press Release Production – We are able to offer our clients assistance with the drafting and review of press releases. We charge $125 per hour for assisting with the drafting and reviewing of press releases.

Email Alerts – Based on the contract a client has with us, we will send out e-mail alerts for any subscribers of our website who opt-in to receive e-mail alerts. E-mail alerts include up to date news and events relevant to a client. We charge $2,500 per news release.

PharmaInvestingNews.com for Viewers

While we expect to generate most of our revenues from our advertising clients, the viewer and user statistics of our website will provide us with the ability to attract new clients. As with most Internet-based advertising companies, it is our plan to develop our website into a user-friendly informational platform where pharmaceutical and biotechnology companies can showcase their businesses and products through multi-dimensional campaigns to viewers searching for that particular information. Website viewers do not have to pay any fees to view our website and search for client information.

Profile Pages – Viewers are able to view our clients’ profile pages and see all facets of the client’s business; including: corporate history, news and events, stock information, all video and/or radio interviews, all press releases put out by the client, and more.

E-mail Subscription Capability – Viewers also have the opportunity to sign up for our e-mail newsletter free of charge. Our e-mail newsletters will be sent out to all of our subscribers as needed or requested by our clients. As with most e-mail subscription newsletters, our subscribers always have the option to opt-out of the subscription to no longer receive our newsletters.

Infrastructure Platform

A stable network of servers and routers capable of handling high internet traffic and large database driven search features is required to support PharmaInvestingNews.com. The database and server infrastructure is outsourced to Hostway.com, (www.hostway.com). The Company has paid for a one-year hosting plan with Hostway.com. At the end of this the first one-year hosting package with Hostway.com, we plan to assess the traffic and usage of our website, and possibly upgrade our services.

Revenue Streams

Coupon Uploads: We will have software developed into the website wherein a small business can upload a coupon pertaining to a certain geographic area and category for a small fee, and pay for the upload directly through our website. We anticipate that this will be the leading source of revenue for our Company.

Affiliate Marketing: By bringing buyers and sellers together to facilitate transactions, affiliate partner commissions are paid by online merchants. When customers click on an advertisement on our website for a product they wish to purchase, the orders will be processed by the "affiliate” partner that then handles fulfillment of the customers’ orders. In other words, TyphoonCoupons.com does not stock or ship any product that is advertised or purchased. The customers’ orders are filled by the actual vendor and the Company receives a commission for driving the customer to the vendor. The Company will implement this Model into various areas of the website.

Advertising Model: We will charge companies to advertise their products to our website visitors, by means such as banner advertising, email campaigns and text message marketing. This Model will be the least used by the Company, but will still be included in our marketing materials and remain an option to businesses.

Plan of Operations

Although we have recently undergone a website renovation, there are still many levels of functionality that we plan to incorporate into our website. Not only do we want to provide the information investors require in order to make an educated investment, we would like to grow into an online community. We would also like to help companies showcase their products. We are attempting to create a vital piece of communication which heretofore has been missing and we want to meet both the demands of our potential viewers and our clients as the main source of company information relating to the pharmaceutical and biotech industry.

Future Revenue Streams

Banner Impressions – We would like to implement banner advertising on our website. We would have advertisers enter into agreements pursuant to which they either pay a fixed fee per thousand banner impressions for a given time-period, usually ranging from a few weeks to one year, or a variable fee depending upon the number of clicks or leads provided to them through our website.

Pay-Per-Click advertising - To further supplement our income, we intend to implement Google AdSense within the pages of PharmaInvestingNews.com. Google AdSense is a free program that enables website publishers of all sizes to display relevant ads on their websites, and earn money. AdSense gives us access to Google's vast network of advertisers, and uses the content included in our website pages to produce ads that are suited to our audience's interests. Also, advertisers with Google can target our website based on demographics, vertical, geographic location, or URL. At any given time, Google will place the highest paying, most relevant advertisements into areas throughout our website, predetermined by us. When any viewer of our website clicks on an advertisement provided by AdSense, we receive money based on the advertisement bid. This method of online advertising is called Pay-Per-Click advertising. Daily reports are provided by Google to show information on how many viewers clicked on each advertisement, and how much revenue was generated by each advertisement.

Affiliate Advertising - Affiliate advertising (using one website to drive traffic to another) is also a form of online advertising, which is frequently overlooked by advertisers, yet we intend to have it integrated it into our website. Affiliates also play a significant role in e-retailers' marketing strategies. Most affiliate programs generally provide revenue sharing or cost per sale (CPS) as a compensation method. When visitors click on an ad from an affiliate advertiser they are directed to the advertiser’s website, then if the visitor purchases a product from the advertiser’s website, the affiliate receives a commission. Cost per sale advertising currently accounts for over 80 percent of online affiliate advertising.

Marketing Strategy

The anticipated marketing strategies discussed herein are for the sole purpose of enhancing our own Company and brand awareness. Even though we are in the industry of promoting other businesses and their products, it is our belief that we will have to develop a reputable name within our niche market in order to gain the attention of larger clients. For this reason, while we continue to promote our current clients and solicit to new clients, we plan to spend substantial funds on marketing our own Company through multiple venues.

Printed Marketing Materials –

Printed marketing materials for our current and future sales representatives will be a key element to growing our client base. We plan to seek out a graphic design company to develop marketing binders for our sales representatives that are eye-catching and contain all the information sales representatives will need to effectively promote and sell our services. We expect the initial cost of these marketing materials to be high because we will be working closely with a designer to create an image-rich portfolio that displays all that we have to offer our clients. However, once the initial design and layout of this portfolio is finished, the only costs involved with providing these marketing materials to our sales representatives are the fairly inexpensive costs of printing and assembling the binders.

Radio Advertising –

We plan to market our Company through investment radio programs and podcasts. We believe that this will not only drive traffic to our website, but may also attract potential clients to our website.

In general, radio advertising costs are broken down into two components. In the first component, the radio advertising strategy is developed and the radio ads themselves are recorded. We plan to budget enough money to create two different advertising spots to test. This way, we can test both ads for an initial period, and choose the ad which performs the best as the control ad. At this point we plan to refine both the control ad and the media elements to maximize the performance of the ad. We will gauge the performance of the ad by the presence of increased traffic to our website and by viewer comments and posts to our website after each advertisement has run. If neither of the first two ads performs above the level that we set, we will have to create more test ads and present different appeals to achieve our desired outcome.

The second component of radio costs is the media budget. The media budget accounts for both preliminary testing and full roll out of our chosen ad. Initially, we will allocate a weekly testing budget, spent early in the campaign, which will focuses in on the strategic, creative, and media variables that could result in maximum profitability. When we do a test, it will run over a four week period. Typically, the budget is higher for the first week, and includes testing of two ads, each with half of the total budget. The second week is typically a lower expenditure. After week two, we will thoroughly analyze the results from week one to identify the variables to test next. In weeks three and four, we plan to continue testing with a slightly lowered budget range.

Once we have identified the most successful ad, we will use the roll-out portion of our radio budget. If an ad exceeds our performance expectations, we will continue with a full advertising campaign.

Google –

We anticipate spending a significant amount of advertising dollars with Google AdWords. We believe that Google AdWords will assist us in driving targeted traffic to our website and provide accurate and measurable website statistics to our advertising clients. Google AdWords puts us in complete control of our marketing spending. There is no minimum spending requirement, and the amount we spend is completely up to us. We believe that our website is not worth anything to our clients unless we are able to drive targeted traffic to our website within our clients’ target market.

Yahoo! Finance –

Yahoo! Finance offers premium advertising, allowing for a wide range of creative options to engage the site’s audience in order to expand the vision, volume, and value of our brand. Yahoo! Finance will enable us to target high-volume, qualified audiences with Yahoo!’s various rich-media options. With a wide range of ad formats, including: streaming, expanding, floating, surveying, wrapping units, and more, Yahoo! can turn our advertisements into attention-grabbing ads that resonate with the right consumers.

We plan to purchase dynamic ad space through Yahoo! Finance, which is a part of Yahoo! Inc. We plan to produce dynamic ads that will appear at the top of every page included in that clients’ profile with Yahoo! Finance, when one of our advertising clients’ stock ticker symbol, or a similar company, is searched for on Yahoo! Finance, We plan to have our advertisements include keyword recognition wherein, when a certain ticker symbol is searched, that ticker symbol will automatically appear within our advertisement. In each case, if a viewer clicks on our advertisements, they will be redirected to our website, which will assist in driving traffic to our website, thereby increasing our market strength.

Facebook –

Facebook Ads are displayed in the right side column on Facebook pages in the ad space. Up to five ads may show at one time on any given page. A viewer will not see an ad running on Facebook unless that viewer is a member of the target audience that was selected for that specific ad. Additionally, even if a viewer is a member, that viewer is not guaranteed to see a specific client’s ad. Facebook allows advertisers to completely customize their advertisements by way of keywords, key demographics (including age, location and interests), as well as daily or monthly budgets. Because Facebook ads are fully customizable, we plan to utilize their systems to drive targeted traffic to our website, thus providing our clients with relevant traffic. We plan to set a daily or monthly budget to advertise to a targeted market that will hopefully represent the niche market that our clients are trying to market their businesses to.

As with Google Adwords, our expenditures and keyword bids will depend on the amount of proceeds that we allocate to our various other marketing strategies. Because Facebook and Google AdWords are so customizable, we plan to start by allocating enough money to each to be able to beat other competitors’ bids on all relevant keywords. We plan to analyze the benefits of our expenditures from month to month, and reallocate marketing funds as needed.

Competition

We face intense competition in the Internet advertising market, generally, from other online advertising and direct marketing networks for a share of client advertising budgets. Although we believe we are attempting to penetrate a niche market, we expect that this competition will continue to intensify in the future as a result of industry consolidation, the maturation of the industry and relatively low barriers to enter into the online advertising sector. Additionally, we do not have exclusive relationships with our clients, who may also advertise with our competitors. Many of the companies that we compete with may be significantly larger and have substantially greater resources than we do.

While it is does not provide the same compilation of information that we provide, we consider FierceMarkets to be our biggest competitor. FierceMarkets Network offers websites within our niche advertising market including: www.fiercepharma.com and www.fiercebiotech.com among others. Another well-known competitor is www.reuters.com. However, Reuters is not as focused on the niche market of pharmaceutical advertising. They simply have one large website containing many sectors and industries, whereas FierceMarkets has entire websites dedicated to providing information to our niche market of viewers.

These companies may be able to engage in larger scale branding and advertising activities than we can, making them more appealing to potential advertisers. Also, not only do we compete with other websites for advertising clients; we also compete with traditional forms of advertising. We are competing with every advertising medium for our potential clients’ advertising dollars.

Our ability to compete depends upon several factors, including, but not limited to the following:

the timing and market acceptance of our new services and enhancements to existing services offered by us;

continuing to maintain good relationships with our current clients;

our customer service and support efforts;

our sales and marketing efforts;

our ability to remain competitive in price.

Employees/Consultants

As of the date of this filing, the Company has no full time employees. We currently rely on our sole officer and director, Robert Lawrence, to manage all aspects of our business. Mr. Lawrence devotes 50-60 hours per week to our Company. We have one independent sales representative that works alongside Mr. Lawrence and is paid on a commission only basis, and devotes 40-60 hours per week to the Company, as necessary. We also use third-party consultants to assist in the ongoing maintenance of our website. We intend to add staff as the Company grows. Any such additions will be made at the judgment of Management to meet the Company's then current needs.

WHERE YOU CAN GET ADDITIONAL INFORMATION

We file annual, quarterly and current reports, proxy statements and other information with the SEC. You may read and copy our reports or other filings made with the SEC at the SEC’s Public Reference Room, located at 100 F Street, N.E., Washington, DC 20549. You can obtain information on the operations of the Public Reference Room by calling the SEC at 1-800-SEC-0330. You can also access these reports and other filings electronically on the SEC’s web site, www.sec.gov.

ITEM 1A.

RISK FACTORS

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 1B.

UNRESOLVED STAFF COMMENTS

None.

ITEM 2.

PROPERTIES

Our corporate headquarters are located at 1810 East Sahara Ave, Suite 1571, Las Vegas, NV 89104, and we are using the space rent-free. As of the date of this filing, we have not sought to move or change our office site. Additional space may be required as we expand our operations. We do not foresee any significant difficulties in obtaining any required additional space. We currently do not own any real property.

ITEM 3.

LEGAL PROCEEDINGS

We know of no material, existing or pending legal proceedings against our company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which our director, officer or any affiliates, or any registered or beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

ITEM 4.

MINE SAFETY DISCLOSURES

Not Applicable.

PART II

ITEM 5.

MARKET FOR THE COMPANY’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Common Stock

As of June 1, 2012, there is no public market for our Common Stock. We intend to contact an authorized OTC Bulletin Board market-maker for sponsorship of our securities on the OTC Bulletin Board.

Record Holders

As of June 1, 2012, an aggregate of 5,361,015 shares of our Common Stock were issued and outstanding and were owned by approximately 33 holders of record, based on information provided by our transfer agent.

Recent Sales of Unregistered Securities

Other than as previously disclosed, none.

Re-Purchase of Equity Securities

None.

Dividends

We have not paid any cash dividends on our Common Stock since inception and presently anticipate that all earnings, if any, will be retained for development of our business and that no dividends on our Common Stock will be declared in the foreseeable future. Any future dividends will be subject to the discretion of our Board of Directors and will depend upon, among other things, future earnings, operating and financial condition, capital requirements, general business conditions and other pertinent facts. Therefore, there can be no assurance that any dividends on our Common Stock will be paid in the future.

Securities Authorized for Issuance Under Equity Compensation Plans

None.

ITEM 6.

SELECTED FINANCIAL DATA

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 7.

MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These forward-looking statements are not historical facts but rather are based on current expectations, estimates and projections. We may use words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “foresee,” “estimate” and variations of these words and similar expressions to identify forward-looking statements. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors, some of which are beyond our control, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted. You should read this report completely and with the understanding that actual future results may be materially different from what we expect. The forward-looking statements included in this report are made as of the date of this report and should be evaluated with consideration of any changes occurring after the date of this Report. We will not update forward-looking statements even though our situation may change in the future and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

RESULTS OF OPERATIONS

Working Capital


	February 29, 2012 $	February 28, 2011 $
Current Assets	12,386	9,000
Current Liabilities	90,363	15,000
Working Capital Deficit	(77,977)	(6,000)

Cash Flows


	Year Ended	Year Ended
	February 29, 2012 $	February 28, 2011 $
Cash Flows used in Operating Activities	(29,408)	(1,000)
Cash Flows from Financing Activities	32,794	10,000
Net increase in Cash During Period	3,386	9,000

Operating Revenues

We have not generated any revenues since inception.

For the Year Ended February 29, 2012

For the year ended February 29, 2012, the Company earned $nil revenues and incurred $84,697of operating expenses, comprised of $74,273 in professional fees relating to accounting, audit, and legal services relating to the Company’s SEC filings, $5,000 in consulting fees, and $5,424 of general and administrative expenses relating to day-to-day operations.

For the Period From February 8, 2011 (Date of Inception) to February 28, 2011

For the period from February 8, 2011 (date of inception) to February 28, 2011, the Company earned $nil of revenues and incurred $6,000 of operating expenses, which included $1,000 of general expenditures, and $5,000 of professional fees relating to the Company’s legal and accounting fees relating to the S-1 registration process.

As at February 29, 2012 and February 28, 2011, the Company had a loss per share of $0.02 and $nil respectively.

LIQUIDITY AND CAPITAL RESOURCES

As at February 29, 2012, the Company had cash and total assets of $12,386 compared with $9,000 at February 28, 2011. The increase in cash and total assets is attributed to financing raised from the issuance of common shares which have not been spent. The Company had total liabilities of $90,363 at February 29, 2012 compared with $15,000 at February 28, 2011. The increase in total liabilities is attributed to increases in accounts payable and accrued liabilities of $50,472 due to unpaid professional fees as the Company had limited cash flow, and increase of $24,891 owing to related parties for amounts contributed by the President and Director of the Company for day-to-day operations.

Cashflows from Operating Activities

During the period ended February 29, 2012, the Company used cash of $29,408 in operating activities compared with $1,000 for the period from February 8, 2011 (date of inception) to February 28, 2011. The increase in cash used for operating activities is attributed to a full period of operating activity during the period.

Cashflows from Investing Activities

During the period ended February 29, 2012, and February 28, 2011, the Company did not have any investing activities.

Cashflows from Financing Activities

During the year ended February 29, 2012, the Company received $32,794 in financing activities for proceeds from issuance of common shares of $12,720 and proceeds from related parties of $20,074. During the period from February 8, 2011 (date of inception) to February 28, 2011, the Company received cash flow of $10,000 from financing activities relating to proceeds from the President and Director of the Company.

Critical Accounting Policies

Our financial statements and accompanying notes have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.

We regularly evaluate the accounting policies and estimates that we use to prepare our financial statements. A complete summary of these policies is included in the notes to our financial statements. In general, management’s estimates are based on historical experience, on information from third-party professionals, and on various other assumptions that are believed to be reasonable under the facts and circumstances. Actual results could differ from those estimates made by management.

Going Concern

We have not attained profitable operations and are dependent upon obtaining financing to pursue any extensive activities. For these reasons, our auditors stated in their report on our audited financial statements that they have substantial doubt that we will be able to continue as a going concern without further financing.

Future Financings

We will continue to rely on equity sales of our common shares in order to continue to fund our business operations. Issuances of additional shares will result in dilution to existing stockholders. There is no assurance that we will achieve any additional sales of the equity securities or arrange for debt or other financing to fund planned acquisitions and activities.

Off-Balance Sheet Arrangements

We have no significant off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

Contractual Obligations

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

Recently Issued Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

ITEM 7A.

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Financial Statements

For the Years Ended February 29, 2012 and February 28, 2011


Report of Independent Registered Public Accounting Firm	F-2
Balance Sheets	F-3
Statements of Operations	F-4
Statements of Cash Flows	F-5
Statements of Stockholders’ Deficit	F-6
Notes to the Financial Statements	F-7

F-1

[f10k022912_10k004.gif]

To the Board of Directors

Pharma Investing News, Inc.

(A Development Stage Company)

We have audited the accompanying balance sheets of Pharma Investing News, Inc., as of February 29, 2012 and February 28, 2011, and the related statements of operations, stockholders’ deficit and cash flows from inception on February 8, 2011 through February 29, 2012. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion the financial statements referred to above present fairly, in all material respects, the financial position of Pharma Investing News, Inc., as of February 29, 2012 and February 28, 2011, and the results of their operations and cash flows from inception on February 8, 2011 through February 29, 2012, in conformity with U.S. generally accepted accounting principles.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company had accumulated losses of $90,697 as of February 29, 2012, which raises substantial doubt about its ability to continue as a going concern. Management’s plans concerning these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ Sadler, Gibb & Associates, LLC

Salt Lake City, UT

June 5, 2012

F-2

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Balance Sheets

(Expressed in US dollars)


	February 29, 2012 $	February 28, 2011 $

ASSETS

Cash	12,386	9,000

Total Assets	12,386	9,000

LIABILITIES

Current Liabilities

Accounts payable	55,472	5,000
Due to related parties	34,891	10,000

Total Liabilities	90,363	15,000

STOCKHOLDERS’ DEFICIT

Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares

	–	–

Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,181,698 and 5,000,000 common shares, respectively

	5,182	5,000

Additional paid-in capital	7,538	(5,000)
Accumulated deficit during the development stage	(90,697)	(6,000)

Total Stockholders’ Deficit	(77,977)	(6,000)

Total Liabilities and Stockholders’ Deficit	12,386	9,000

(The accompanying notes are an integral part of these financial statements)

F-3

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Statements of Operations

(Expressed in US dollars)


	For the year ended February 29, 2012 $	For the period from February 8, 2011 (date of inception) to February 28, 2011 $	Accumulated from February 8, 2011 (date of inception) to February 29, 2012 $

Revenues	–	–	–

Operating Expenses

Consulting fees	5,000	–	5,000
General and administrative	5,424	1,000	6,424
Professional fees	74,273	5,000	79,273

Total Operating Expenses	84,697	6,000	90,697

Net Loss	(84,697)	(6,000)	(90,697)
Net Loss per Share – Basic and Diluted	(0.02)	(0.00)	–
Weighted Average Shares Outstanding – Basic and Diluted	5,012,282	5,000,000	–

(The accompanying notes are an integral part of these financial statements)

F-4

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Statements of Cash Flows

(Expressed in US dollars)


	For the year ended February 29, 2012 $	For the period from February 8, 2011 (date of inception) to February 28, 2011 $	Accumulated from February 8, 2011 (date of inception) to February 29, 2012 $

Operating Activities

Net loss for the period	(84,697)	(6,000)	(90,697)

Changes in operating assets and liabilities:

Accounts payable	50,472	5,000	55,472
Expenses paid by related parties	4,817	–	4,817

Net Cash Used In Operating Activities	(29,408)	(1,000)	(30,408)

Financing Activities

Proceeds from related party	20,074	10,000	30,074
Proceeds from issuance of common shares	12,720	–	12,720

Net Cash Provided by Financing Activities	32,794	10,000	42,794

Change in Cash	3,386	9,000	12,386

Cash – Beginning of Period	9,000	–	–

Cash – End of Period	12,386	9,000	12,386


Supplemental Disclosures

Interest paid	–	–	–
Income tax paid	–	–	–

(The accompanying notes are an integral part of these financial statements)

F-5

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Statements of Stockholders’ Deficit

(Expressed in US dollars)


	Common Stock		Additional	Accumulated
	Shares	Par Value	Paid-In Capital	Deficit	Total
	#	$	$	$	$

Balance – February 8, 2011 (date of inception)	–	–	–	–	–

Issuance of founders shares	5,000,000	5,000	(5,000)	–	–

Net loss for the period	–	–	–	(6,000)	(6,000)
	–	–
Balance – February 28, 2011	5,000,000	5,000	(5,000)	(6,000)	(6,000)

Common stock issued for cash	181,698	182	12,538	–	12,720

Net loss for the year	–	–	–	(84,697)	(84,697)
	–	–
Balance – February 29, 2012	5,181,698	5,182	7,538	(90,697)	(77,977)

(The accompanying notes are an integral part of these financial statements)

F-6

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Notes to the Financial Statements

(Expressed in US dollars)

Nature of Operations and Continuance of Business

Pharma Investing News, Inc. (the “Company”) was incorporated in the State of Nevada on February 8, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915, Development Stage Entities.

Going Concern

These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of February 29, 2012, the Company has not recognized any revenue, and has a working capital deficit and an accumulated deficit of $90,697. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

Summary of Significant Accounting Policies

Basis of Presentation

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is February 28.

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

Cash and cash equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

F-7

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Notes to the Financial Statements

(Expressed in US dollars)

Summary of Significant Accounting Policies (continued)

Basic and Diluted Net Loss per Share

The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.

Financial Instruments

Pursuant to ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, accounts payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

Comprehensive Loss

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of February 29, 2012, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

F-8

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Notes to the Financial Statements

(Expressed in US dollars)

Summary of Significant Accounting Policies (continued)

Recent Accounting Pronouncements

Income Taxes

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 “Accounting for Income Taxes” as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

Related Party Transactions

During the periods ended February 29, 2012 and February 28, 2011, the Company’s President and CEO advanced $20,074 and $10,000, respectively, to the Company and paid expenses in the amount of $4,817 and $0, respectively, on behalf of the Company. Accordingly, these amounts have been recorded as due to related parties in the amounts of $34,891 and $10,000 at February 29, 2012 and February 28, 2011. The amounts owing are unsecured, non-interest bearing, and due on demand.

Common Shares

During January and February 2012, the Company received cash of $12,720 in exchange for 181,698 shares of the Company’s common stock.

Income Taxes

The Company has $90,697 of net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2031. The income tax benefit differs from the amount computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at February 29, 2012, the Company had no uncertain tax positions.


	February 29, 2012 $	February 28, 2011 $

Net loss before taxes	(84,697)	(6,000)
Statutory rate	34%	34%

Computed expected tax recovery	28,797	2,040
Valuation allowance	(28,797)	(2,040)

Income tax provision	–	–

F-9

PHARMA INVESTING NEWS, INC.

(A Development Stage Company)

Notes to the Financial Statements

(Expressed in US dollars)

Income Taxes (continued)

The significant components of deferred income tax assets and liabilities at February 29, 2012 and February 28, 2011 are as follows:


	February 29, 2012 $	February 28, 2011 $

Net operating loss carried forward	30,837	2,040

Valuation allowance	(30,837)	(2,040)

Net deferred income tax asset	–	–

Subsequent Events

During March through May, the Company received cash of $12,550 in exchange for 179,317 shares of the Company’s common stock.

In accordance with ASC 855-10 the Company has analyzed its operations subsequent from February 29, 2012 through the date these financial statements were issued, and has determined there are no material subsequent events to disclose in these financial statements.

F-10

ITEM 9.

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A.

CONTROLS AND PROCEDURES.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) promulgated under the Securities Exchange Act of 1934 (the "Exchange Act"), that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of February 29, 2012. Based on the evaluation of these disclosure controls and procedures, and in light of the material weaknesses found in our internal controls over financial reporting, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Under the supervision and with the participation of management, including the Chief Executive Officer and Chief Financial Officer, the Company conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting as of February 29, 2012, using the criteria established in “Internal Control - Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO").

A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. In its assessment of the effectiveness of internal control over financial reporting as of February 29, 2012, the Company determined that there were control deficiencies that constituted material weaknesses, as described below.


	1.	We do not have an Audit Committee – While not being legally obligated to have an audit committee, it is the management’s view that such a committee, including a financial expert member, is an utmost important entity level control over the Company’s financial statements. Currently the Board of Directors acts in the capacity of the Audit Committee, and does not include a member that is considered to be independent of management to provide the necessary oversight over management’s activities.

	2.	We did not maintain appropriate cash controls – As of February 29, 2012, the Company has not maintained sufficient internal controls over financial reporting for the cash process, including failure to segregate cash handling and accounting functions, and did not require dual signature on the Company’s bank accounts. Alternatively, the effects of poor cash controls were mitigated by the fact that the Company had limited transactions in their bank accounts.

	3.	We did not implement appropriate information technology controls – As at February 29, 2012, the Company retains copies of all financial data and material agreements; however there is no formal procedure or evidence of normal backup of the Company’s data or off-site storage of the data in the event of theft, misplacement, or loss due to unmitigated factors.

Accordingly, the Company concluded that these control deficiencies resulted in a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis by the company’s internal controls.

As a result of the material weaknesses described above, management has concluded that the Company did not maintain effective internal control over financial reporting as of February 29, 2012 based on criteria established in Internal Control—Integrated Framework issued by COSO.

Changes in Internal Control over Financial Reporting

There has been no change in our internal control over financial reporting identified in connection with our evaluation we conducted of the effectiveness of our internal control over financial reporting as of February 29, 2012, that occurred during our fourth fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

This annual report does not include an attestation report of the Company’s registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by the Company’s registered public accounting firm pursuant to temporary rules of the SEC that permit the Company to provide only management’s report in this annual report.

Continuing Remediation Efforts to address deficiencies in Company’s Internal Control over Financial Reporting

Once the Company is engaged in a business of merit and has sufficient personnel available, then our Board of Directors, in particular and in connection with the aforementioned deficiencies, will establish the following remediation measures:


	1.	Our Board of Directors will nominate an audit committee or a financial expert on our Board of Directors in the next fiscal year.

	2.	We will appoint additional personnel to assist with the preparation of the Company’s monthly financial reporting, including preparation of the monthly bank reconciliations.

ITEM 9B.

OTHER INFORMATION.

None.

PART III

ITEM 10.

DIRECTORS AND EXECUTIVE OFFICERS.

Identification of Directors and Executive Officers

The following table sets forth the names and ages of our current director(s) and executive officer(s):


Name	Age	Position with the Company	Director Since
Robert Lawrence	26	CEO, CFO, President, Treasurer, Secretary, Chairman & Director	February 8, 2011

The board of directors has no nominating, audit or compensation committee at this time.

Term of Office

Each of our officers is elected by the Company’s Board of Directors to serve until the next annual meeting of Directors or until their successors are duly elected and qualified. Each of our directors is elected by the Company’s Board of Directors and shall hold office until the next annual meeting of stockholders and until his/her successor shall have been duly elected and qualified.

Background and Business Experience

The business experience during the past five years of the person presently listed above as an Officer or Director of the Company is as follows:

Robert Lawrence – In May 2005, Mr. Lawrence graduated from Capilano University in Vancouver, B.C., with a certificate in Retail Marketing. From May 2005 until May 2008, Mr. Lawrence traveled and developed a passion for national and international healthcare companies. From May 2008 to February 2009, Mr. Lawrence worked for the Guthrie Philips Group, a company which specialized in banking, lending, and collection software for companies, as an account executive. As account executive, Mr. Lawrence sold collection recovery and other banking software to Banks, and CEOs and other executives of national and international companies. From February 2009 until just recently, Mr. Lawrence had assisted private and publicly traded companies with their marketing and online web strategies. Additionally, towards the end of 2008, Mr. Lawrence developed and launched PharmaInvestingNews.com. Mr. Lawrence devotes 50-60 hours per week on the operations of the Company, and will adjust his schedule accordingly if more time is needed. The Company decided Mr. Lawrence would be a good President because of his marketing and computer skills, his passion for transactions involving national and international healthcare companies, and his willingness to devote time to help grow the Company.

Identification of Significant Employees

We have no significant employees other than Mr. Robert Lawrence, our President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Chairman and Director.

Family Relationship

We currently do not have any officers or directors of our Company who are related to each other.

Involvement in Certain Legal Proceedings

During the past ten years no director, executive officer, promoter or control person of the Company has been involved in the following:

(1)

A petition under the Federal bankruptcy laws or any state insolvency law which was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

(2)

Such person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

(3)

Such person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

ii.

Engaging in any type of business practice; or

iii.

Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

(4)

Such person was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

(5)

Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

(6)

Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

(7)

Such person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

Any Federal or State securities or commodities law or regulation; or

ii.

Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

iii.

Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

(8)

Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Audit Committee and Audit Committee Financial Expert

The Company does not have an audit committee or an audit committee financial expert (as defined in Item 407 of Regulation S-K) serving on its Board of Directors. All current members of the Board of Directors lack sufficient financial expertise for overseeing financial reporting responsibilities. The Company has not yet employed an audit committee financial expert on its Board due to the inability to attract such a person.

The Company intends to establish an audit committee of the board of directors, which will consist of independent directors. The audit committee’s duties will be to recommend to the Company’s board of directors the engagement of an independent registered public accounting firm to audit the Company’s financial statements and to review the Company’s accounting and auditing principles. The audit committee will review the scope, timing and fees for the annual audit and the results of audit examinations performed by the internal auditors and independent registered public accounting firm, including their recommendations to improve the system of accounting and internal controls. The audit committee will at all times be composed exclusively of directors who are, in the opinion of the Company’s board of directors, free from any relationship which would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles.

Code of Ethics

We have adopted a Code of Ethics (the “Code”) that applies to our directors, officers and employees, including our Chief Executive Officer and Chief Financial Officer. A written copy of the Code is available on written request to the Company and was filed with the SEC on May 17, 2011, as part of the Company’s Registration Statement on Form S-1 that is incorporated by reference hereto as Exhibit 14.01.

Section 16(a) Beneficial Ownership Reporting Compliance

We do not yet have a class of equity securities registered under the Securities Exchange Act of 1934, as amended. Hence, compliance with Section 16(a) thereof by our officers and directors is not required.

ITEM 11.

EXECUTIVE COMPENSATION

The following table sets forth the compensation paid to our executive officers during the twelve month periods ended February 29, 2012 and February 28, 2011:

Summary Compensation Table


Name and Principal Position		Fiscal Year Ended	Salary ($)	Bonus ($)	Stock Awards ($)	Option Awards ($)	Non-Equity Incentive Plan Compensation ($)	Nonqualified Deferred Compensation Earnings ($)	All Other Compensation ($)	Total ($)
Robert Lawrence President, CEO, CFO, Treasurer, Secretary, Chairman and Director		2/29/2012	-0-	-0-	-0-	-0-	-0-	-0-	-0-	-0-
		2/28/2011	-0-	-0-	5,000⁽¹⁾	-0-	-0-	-0-	-0-	5,000
(1)	The stock awards to Mr. Lawrence were issued beginning February 8, 2011 for services rendered in connection with the formation of the Company. This dollar estimate is based on the grant date aggregate fair value at the close of business in accordance with FASB ASC Topic 718.

Narrative Disclosure to Summary Compensation Table

There are no employment contracts, compensatory plans or arrangements, including payments to be received from the Company with respect to any executive officer, that would result in payments to such person because of his or her resignation, retirement or other termination of employment with the Company, or its subsidiaries, any change in control, or a change in the person’s responsibilities following a change in control of the Company.

Outstanding Equity Awards at Fiscal Year-End

No executive officer received any equity awards, or holds exercisable or unexercisable options, as of the year ended February 29, 2012.

Long-Term Incentive Plans

There are no arrangements or plans in which we provide pension, retirement or similar benefits for directors or executive officers.

Compensation Committee

We currently do not have a compensation committee of the Board of Directors. The Board of Directors as a whole determines executive compensation.

Compensation of Directors

Our directors receive no extra compensation for their service on our Board of Directors.

ITEM 12.

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

Security Ownership of Management

The following table sets forth certain information concerning the number of shares of our Common Stock owned beneficially as of June 1, 2012, by: (i) our directors; (ii) our named executive officer; and (iii) each person or group known by us to beneficially own more than 5% of our outstanding shares of common stock. Unless otherwise indicated, the shareholders listed below possess sole voting and investment power with respect to the shares they own.


Name and Address of Beneficial Owner	Title of Class	Amount and Nature of Beneficial Ownership⁽¹⁾ (#)	Percent of Class⁽²⁾ (%)
Robert Lawrence⁽³⁾ 1810 East Sahara Ave Suite 1571 Las Vegas, NV 89104	Common	5,000,000	93.27%
All Officers and Directors as a Group (1 Person)	Common	5,000,000	93.27%


1.	The number and percentage of shares beneficially owned is determined under rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which the individual has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60 days through the exercise of any stock option or other right. The persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to community property laws where applicable and the information contained in the footnotes to this table.

2.	Based on 5,361,015 issued and outstanding shares of Common Stock as of June 1, 2012.

3.	Robert Lawrence is the Company’s President, CEO, CFO, Secretary, Treasurer, Chairman and Director. His beneficial ownership includes 5,000,000 common shares.

Changes in Control

There are no present arrangements or pledges of the Company’s securities which may result in a change in control of the Company.

ITEM 13.

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

Related Party Transactions

Other than the foregoing, none of the directors or executive officers of the Company, nor any person who owned of record or was known to own beneficially more than 5% of the Company’s outstanding shares of its Common Stock, nor any associate or affiliate of such persons or companies, has any material interest, direct or indirect, in any transaction that has occurred during the past fiscal year, or in any proposed transaction, which has materially affected or will affect the Company.

With regard to any future related party transaction, we plan to fully disclose any and all related party transactions in the following manner:

Disclosing such transactions in reports where required;

Disclosing in any and all filings with the SEC, where required;

Obtaining disinterested directors consent; and

Obtaining shareholder consent where required.

Director Independence

For purposes of determining director independence, we have applied the definitions set out in NASDAQ Rule 5605(a)(2). The NASDAQ definition of “Independent Officer” means a person other than an Executive Officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company's Board of Directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director.

According to the NASDAQ definition, Robert Lawrence is not an independent director because he is also an executive officer of the Company.

Review, Approval or Ratification of Transactions with Related Persons

We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934 and are not required to provide the information under this item.

ITEM 14.

PRINCIPAL ACCOUNTANT FEES AND SERVICES.


		Year Ended February 29, 2012		Year Ended February 28, 2011
Audit fees	$	10,000	$	2,000
Audit-related fees	$	0	$	0
Tax fees	$	0	$	0
All other fees	$	0	$	0
Total	$	10,000	$	2,000

Audit Fees

During the fiscal year ended February 29, 2012, we incurred approximately $10,000 in fees to our principal independent accountants for professional services rendered in connection with the audit and reviews of our financial statements for fiscal year ended February 29, 2012.

During the fiscal year ended February 28, 2011, we incurred approximately $2,000 in fees to our principal independent accountants for professional services rendered in connection with the audit and reviews of our financial statements for fiscal year ended February 28, 2011.

Audit-Related Fees

The aggregate fees billed during the fiscal years ended February 29, 2012 and February 28, 2011 for assurance and related services by our principal independent accountants that are reasonably related to the performance of the audit or review of our financial statements (and are not reported under Item 9(e)(1) of Schedule 14A) was $0 and $0, respectively.

Tax Fees

The aggregate fees billed during the fiscal years ended February 29, 2012 and February 28, 2011 for professional services rendered by our principal accountant tax compliance, tax advice and tax planning were $0 and $0, respectively.

All Other Fees

The aggregate fees billed during the fiscal years ended February 29, 2012 and February 28, 2011 for products and services provided by our principal independent accountants (other than the services reported in Items 9(e)(1) through 9(e)(3) of Schedule 14A) was $0 and $880, respectively.

PART IV

ITEM 15.

EXHIBITS.

(a)

Exhibits


Exhibit Number	Description of Exhibit	Filing
3.01	Articles of Incorporation	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
3.02	Bylaws	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
10.01	Promissory Note between the Company and Robert Lawrence Dated April 18, 2011	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
10.02	Joint Venture Agreement between the Company and Healthcare Media Dated July 22, 2011	Filed with the SEC on July 27, 2011 as part of our Amended Registration Statement on Form S-1/A.
10.03	Promissory Note between the Company and Robert Lawrence Dated August 25, 2011	Filed with the SEC on August 30, 2011 as part of our Amended Registration Statement on Form S-1/A.
10.04	Promissory Note between the Company and Robert Lawrence Dated August 26, 2011	Filed with the SEC on August 30, 2011 as part of our Amended Registration Statement on Form S-1/A.
14.01	Code of Ethics	Filed with the SEC on May 17, 2011 as part of our Registration Statement on Form S-1.
31.01	Certification of Principal Executive Officer Pursuant to Rule 13a-14	Filed herewith.
31.02	Certification of Principal Financial Officer Pursuant to Rule 13a-14	Filed herewith.
32.01	CEO and CFO Certification Pursuant to Section 906 of the Sarbanes-Oxley Act	Filed herewith.
101.INS*	XBRL Instance Document	Filed herewith.
101.SCH*	XBRL Taxonomy Extension Schema Document	Filed herewith.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document	Filed herewith.
101.LAB*	XBRL Taxonomy Extension Labels Linkbase Document	Filed herewith.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document	Filed herewith.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document	Filed herewith.

*Pursuant to Regulation S-T, this interactive data file is deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, and otherwise is not subject to liability under these sections.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PHARMA INVESTING NEWS, INC.

Dated: June 12, 2012

/s/ Robert Lawrence

By: Robert Lawrence

Its: President, Principal Executive Officer, Principal Financial Officer, Principal Accounting Officer, Secretary and Treasurer

Pursuant to the requirement of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Company and in the capacities and on the dates indicated:

Dated: June 12, 2012

/s/ Robert Lawrence

By: Robert Lawrence

Its: Director

SUPPLEMENTAL INFORMATION TO BE FURNISHED WITH REPORTS FILED

PURSUANT TO SECTION 15(d) OF THE EXCHANGE ACT BY NON-REPORTING ISSUERS

No annual report to security holders covering the company’s last fiscal year has been sent as of the date of this report

No proxy statement, form of proxy, or other proxy soliciting material relating to the company’s last fiscal year has been sent to any of the company’s security holders with respect to any annual or other meeting of security holders.

If such report or proxy material is furnished to security holders subsequent to the filing of this Annual Report on Form 10-K, the company will furnish copies of such material to the Commission at the time it is sent to security holders.

EX-31.1 2 f10k022912_ex31z1.htm EXHIBIT 31.1 SECTION 302 CERTIFICATION Exhibit 31.1 Section 302 Certification

Exhibit 31.01

CERTIFICATION OF THE CHIEF EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Robert Lawrence, certify that:

I have reviewed this Annual Report on Form 10-K of Pharma Investing News, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 12, 2012

/s/ Robert Lawrence

By: Robert Lawrence

Its: Chief Executive Officer

EX-31.2 3 f10k022912_ex31z2.htm EXHIBIT 31.2 SECTION 302 CERTIFICATION Exhibit 31.2 Section 302 Certification

Exhibit 31.02

CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO RULE 13a-14

I, Robert Lawrence, certify that:

I have reviewed this Annual Report on Form 10-K of Pharma Investing News, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: June 12, 2012

/s/ Robert Lawrence

By: Robert Lawrence

Its: Chief Financial Officer

EX-32.1 4 f10k022912_ex32z1.htm EXHIBIT 32.1 SECTION 906 CERTIFICATION Exhibit 32.1 Section 906 Certification

Exhibit 32.01

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Pharma Investing News, Inc. (the “Company”) on Form 10-K for the year ending February 29, 2012, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Robert Lawrence, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Robert Lawrence

By: Robert Lawrence

Chief Executive Officer and Chief Financial Officer

Dated: June 12, 2012

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

EX-101.INS 5 pini-20120229.xml XBRL INSTANCE DOCUMENT 10-K 2012-02-29 false PHARMA INVESTING NEWS, INC. 0001520047 --02-28 5361015 0 Smaller Reporting Company Yes No No 2013 FY

12386

9000

12386

9000

55472

5000

34891

10000

90363

15000

5182

5000

7538

-5000

-90697

-6000

-77977

-6000

12386

9000

0.001

10000000

0.001

290000000

5181698

5000000

5181698

5000000

5000 0 5000

5424

1000

6424

74273

5000

79273

84697

6000

90697

-84697

-6000

-90697

-0.02

0.00

5012282 5000000

-84697

-6000

-90697

50472

5000

55472

4817

-29408

-1000

-30408

20074

10000

30074

12720

32794

10000

42794

3386

9000

12386

1. Nature of Operations and Continuance of Business   Pharma Investing News, Inc. (the Company) was incorporated in the State of Nevada on February 8, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 915, Development Stage Entities.   Going Concern   These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of February 29, 2012, the Company has not recognized any revenue, and has a working capital deficit and an accumulated deficit of $90,697. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Companys future operations. These factors raise substantial doubt regarding the Companys ability to continue as a going concern.  These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

2. Summary of Significant Accounting Policies   a) Basis of Presentation   The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) and are expressed in U.S. dollars.  The Companys fiscal year end is February 28.   b) Use of Estimates   The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.   c) Cash and cash equivalents   The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.     d) Basic and Diluted Net Loss per Share   The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.   e) Financial Instruments   Pursuant to ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instruments categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:   Level 1   Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.   Level 2   Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.   Level 3   Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.   The Companys financial instruments consist principally of cash, accounts payable, and amounts due to related parties.  Pursuant to ASC 820, the fair value of our cash is determined based on Level 1 inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.   f) Comprehensive Loss   ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of February 29, 2012, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.   g) Recent Accounting Pronouncements   The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.   h) Income Taxes   Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 Accounting for Income Taxes as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

3. Related Party Transactions   During the periods ended February 29, 2012 and February 28, 2011, the Companys President and CEO advanced $20,074 and $10,000, respectively, to the Company and paid expenses in the amount of $4,817 and $0, respectively, on behalf of the Company. Accordingly, these amounts have been recorded as due to related parties in the amounts of $34,891 and $10,000 at February 29, 2012 and February 28, 2011. The amounts owing are unsecured, non-interest bearing, and due on demand.

4. Common Shares   During January and February 2012, the Company received cash of $12,720 in exchange for 181,698 shares of the Companys common stock.

5. Income Taxes   The Company has $90,697 of net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2031.  The income tax benefit differs from the amount computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at February 29, 2012, the Company had no uncertain tax positions.     <div align="center"> <table cellpadding="0" cellspacing="0"> <tr> <td width="360" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td> <td width="24" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td> <td width="108" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td> <td width="110" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td></tr> <tr> <td width="360" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="24" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> February 29, 2012 $</td> <td width="110" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> February 28, 2011 $</td></tr> <tr> <td width="360" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="24" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="110" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td></tr> <tr> <td width="360" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Net loss before taxes</td> <td width="24" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> (84,697)</td> <td width="110" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> (6,000)</td></tr> <tr> <td width="360" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Statutory rate</td> <td width="24" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> 34%</td> <td width="110" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> 34%</td></tr> <tr> <td width="360" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="24" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="110" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td></tr> <tr> <td width="360" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Computed expected tax recovery</td> <td width="24" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> 28,797</td> <td width="110" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> 2,040</td></tr> <tr> <td width="360" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Valuation allowance</td> <td width="24" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> (28,797)</td> <td width="110" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> (2,040)</td></tr> <tr> <td width="360" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:black 1pt solid; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="24" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:black 1pt solid; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:black 1pt solid; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="110" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:black 1pt solid; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td></tr> <tr> <td width="360" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:3.75in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Income tax provision</td> <td width="24" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:0.25in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="108" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:81pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> </td> <td width="110" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:82.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> </td></tr></table></div>     The significant components of deferred income tax assets and liabilities at February 29, 2012 and February 28, 2011 are as follows:   <div align="center"> <table cellpadding="0" cellspacing="0"> <tr> <td width="347" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td> <td width="15" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td> <td width="96" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td> <td width="18" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td> <td width="102" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in"></td></tr> <tr> <td width="347" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="15" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="96" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> February 29, 2012 $</td> <td width="18" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom">  </td> <td width="102" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="bottom"> February 28, 2011 $</td></tr> <tr> <td width="347" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="15" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="96" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="18" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="102" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td></tr> <tr> <td width="347" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Net operating loss carried forward</td> <td width="15" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="96" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> 30,837</td> <td width="18" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="102" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> 2,040</td></tr> <tr> <td width="347" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="15" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="96" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="18" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="102" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td></tr> <tr> <td width="347" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Valuation allowance</td> <td width="15" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="96" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> (30,837)</td> <td width="18" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="102" style="BORDER-BOTTOM:black 1pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> (2,040)</td></tr> <tr> <td width="347" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="15" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="96" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="18" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="102" style="BORDER-BOTTOM:#ece9d8; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td></tr> <tr> <td width="347" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:260.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> Net deferred income tax asset</td> <td width="15" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:11.25pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="96" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:1in; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> </td> <td width="18" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:13.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top">  </td> <td width="102" style="BORDER-BOTTOM:black 1.5pt solid; BORDER-LEFT:#ece9d8; PADDING-BOTTOM:0in; BACKGROUND-COLOR:transparent; PADDING-LEFT:0in; WIDTH:76.5pt; PADDING-RIGHT:0in; BORDER-TOP:#ece9d8; BORDER-RIGHT:#ece9d8; PADDING-TOP:0in" valign="top"> </td></tr></table></div>

6. Subsequent Events   During March through May, the Company received cash of $12,550 in exchange for 179,317 shares of the Companys common stock.   In accordance with ASC 855-10 the Company has analyzed its operations subsequent from February 29, 2012 through the date these financial statements were issued, and has determined there are no material subsequent events to disclose in these financial statements.

5000000 5000 -5000 0 0 0 0 -6000 -6000

5000000

5000

-5000

-6000

181698

182

12538

12720

0 0 -84697 -84697

5181698

5182

7538

-90697

-77977

0001520047 2011-03-01 2012-02-29 0001520047 2012-06-06 0001520047 2012-02-29 0001520047 2011-02-28 0001520047 2011-02-09 2011-02-28 0001520047 2011-02-09 2012-02-29 0001520047 2011-02-07 0001520047 us-gaap:CapitalUnitsMember 2011-02-08 0001520047 us-gaap:CommonStockMember 2011-02-08 0001520047 us-gaap:AdditionalPaidInCapitalMember 2011-02-08 0001520047 us-gaap:RetainedEarningsMember 2011-02-08 0001520047 us-gaap:ParentMember 2011-02-08 0001520047 us-gaap:CapitalUnitsMember 2011-02-09 2011-02-28 0001520047 us-gaap:CommonStockMember 2011-02-09 2011-02-28 0001520047 us-gaap:AdditionalPaidInCapitalMember 2011-02-09 2011-02-28 0001520047 us-gaap:RetainedEarningsMember 2011-02-09 2011-02-28 0001520047 us-gaap:ParentMember 2011-02-09 2011-02-28 0001520047 us-gaap:CapitalUnitsMember 2011-02-28 0001520047 us-gaap:CommonStockMember 2011-02-28 0001520047 us-gaap:AdditionalPaidInCapitalMember 2011-02-28 0001520047 us-gaap:RetainedEarningsMember 2011-02-28 0001520047 us-gaap:ParentMember 2011-02-28 0001520047 us-gaap:CapitalUnitsMember 2011-03-01 2012-02-29 0001520047 us-gaap:CommonStockMember 2011-03-01 2012-02-29 0001520047 us-gaap:AdditionalPaidInCapitalMember 2011-03-01 2012-02-29 0001520047 us-gaap:RetainedEarningsMember 2011-03-01 2012-02-29 0001520047 us-gaap:ParentMember 2011-03-01 2012-02-29 0001520047 us-gaap:CapitalUnitsMember 2012-02-29 0001520047 us-gaap:CommonStockMember 2012-02-29 0001520047 us-gaap:AdditionalPaidInCapitalMember 2012-02-29 0001520047 us-gaap:RetainedEarningsMember 2012-02-29 0001520047 us-gaap:ParentMember 2012-02-29 iso4217:USD shares iso4217:USD shares EX-101.CAL 6 pini-20120229_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 pini-20120229_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 pini-20120229_lab.xml XBRL TAXONOMY EXTENSION LABELS LINKBASE DOCUMENT Issuance of founders shares Issuance of founders shares during the period Change in Cash Change in Cash Total Operating Expenses Total Operating Expenses Income Taxes Revenues Entity Public Float Entity Current Reporting Status Entity Common Stock, Shares Outstanding Net loss for the year The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Financing Activities Professional fees Common Stock, shares outstanding Total Assets Total Assets Entity Registrant Name Income Taxes {1} Income Taxes Related Party Transactions {1} Related Party Transactions Common stock issued for cash Supplemental Disclosures Expenses paid by related parties Due to related parties Related Party Transactions Net Cash Provided by Financing Activities Net Cash Provided by Financing Activities Weighted Average Shares Outstanding - Basic and Diluted The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS. Operating Expenses {1} Operating Expenses Total Liabilities and Stockholders' Deficit Total Liabilities and Stockholders' Deficit Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,181,698 and 5,000,000 common shares, respectively Total Liabilities Total Liabilities Accounts payable Current Liabilities Statement [Line Items] Entity Voluntary Filers Document and Entity Information Common Stock, shares issued Amendment Flag Proceeds from issuance of common shares Proceeds from related party Net Loss Net Loss Accumulated deficit during the development stage Statement [Table] Current Fiscal Year End Date Entity Central Index Key Summary of Significant Accounting Policies {1} Summary of Significant Accounting Policies Subsequent Events Summary of Significant Accounting Policies Document Fiscal Period Focus Entity Filer Category Nature of Operations and Continuance of Business {1} Nature of Operations and Continuance of Business Common stock Par Value CHANGES IN STOCKHOLDERS DEFICIT Consulting fees The charge during the reporting period towards consultation charges Common Shares {1} Common Shares Common Shares Nature of Operations and Continuance of Business Common Stock, par value Net loss for the period {1} Net loss for the period The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Common Stock Shares Operating Activities Total Stockholders' Deficit Total Stockholders' Deficit Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares ASSETS Subsequent Events {1} Subsequent Events Accumulated deficit Additional paid-in capital {1} Additional paid-in capital Net Cash Used In Operating Activities Net Cash Used In Operating Activities Accounts payable {1} Accounts payable Net Loss per Share - Basic and Diluted General and administrative Preferred Stock, par value Document Fiscal Year Focus Interest paid Net loss for the period Additional paid-in capital Entity Well-known Seasoned Issuer Document Type Total Revenues {1} Revenues Common Stock, shares authorized Statement, Equity Components [Axis] Changes in operating assets and liabilities: LIABILITIES Document Period End Date Balance Balance Balance Income tax paid Preferred Stock, shares authorized Parentheticals STOCKHOLDERS' DEFICIT Cash {1} Cash Cash - Beginning of Period Cash - End of Period EX-101.PRE 9 pini-20120229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT EX-101.SCH 10 pini-20120229.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 000030 - Statement - Balance Sheets Parentheticals link:presentationLink link:definitionLink link:calculationLink 000020 - Statement - Balance Sheets link:presentationLink link:definitionLink link:calculationLink 000060 - Disclosure - Nature of Operations and Continuance of Business link:presentationLink link:definitionLink link:calculationLink 000050 - Statement - Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 000070 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 000090 - Disclosure - Common Shares link:presentationLink link:definitionLink link:calculationLink 000010 - Document - Document and Entity Information link:presentationLink link:definitionLink link:calculationLink 000040 - Statement - Statements of Operations link:presentationLink link:definitionLink link:calculationLink 000080 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 000055 - Statement - Statements of Stockholders' Deficit link:presentationLink link:definitionLink link:calculationLink 000110 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 000100 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink GRAPHIC 11 f10k022912_10k002.gif IMAGE begin 644 f10k022912_10k002.gif M1TE&.#EAPP"&`/<`````````,P``9@``F0``S```_P`S```S,P`S9@`SF0`S MS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9_P#,``#, M,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`9C,`F3,` MS#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F_S.9`#.9 M,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_9C/_F3/_ MS#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S_V9F`&9F M,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,9F;,F6;, MS&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`_YDS`)DS M,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF99IF9F9F9 MS)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G__\P``,P` M,\P`9LP`FN7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7?^[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUS_ M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUR#SC777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<_W/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS34`N7;MVK5KUZY=NW;MVK5KUZY=N_;ERZ`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`Y? M[/!%(M=<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<__--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777*/#%S7L\$4BUUQSS3777'/--==<<\TU MUUQSS36#[%##%SOLT,HUUR3RQ0X[T)#(-==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUP#D&O7KEV[=NW:M6O7 MKEV[=NW:M6O_UZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZ[M^++CRXY$ MUZY=NW;MVK5KUZY=NW;MVK5KUW9\V?%EQY=KUQ+M\++C2Z)KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW8MRXX=7FHD_[IV[=JU M:]>N7;MV[=HUUUQSS377)++#%S5XL<,UUR22Q0Y?[)#(-==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 MH'/--=?L\,4..WR1R#777'/--==<<\TUU_]<<\TUUUQSS36)>+'##CM\<)M#++-==<<\TUUUQSS3777'/--==<,TLK MB23RQ2!E#)((*[-<<\TUUUQSS3777'/--==<<\TUUUQSS36SM)+(%U]<<\TU MUUQSS3777'--*ZTD\L47B21RS3777'/--==<<\TUK212QB!?)))(--=<<\TU MUUQSS3777'/--==<<\TLK20RR!=?)/)%(JW,RP0Q8[[/#%#E^T/'%#CMXL<,.6>Q01BO77'/- M-=-+ MHFO7KEV[=NW:M6O7KEV[=NW:M6NMONS8\67'M6N)LNSXLJ/5M40U=GS9_['C MRXX=7W34^+*CU;5KUZY=NW;MVJPO7W;LR+)CQY<=7W9\J?%EQXXOUZY=NW;M MVHXO.W9\N7:ME8XO.W9DV;$CT9<=7W9[+###E_HL,,7 MUUQSS377Z)#%#E]X<4TK.V2Q@PY?[+##%XGHD,4..USSQ0XU[/#%#E_LL,,7 M.WRQPPY?S#++%UGLL,,..WRQPQ<[[/!%#5_HD,@UUUQSS377M/+%#CMDL<,. M7^SPQ0X[?+'#%SM\L<,.7UQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQS#3K77'/-#CMDL<,.B5QSS3777'/--==<<\TUUUQSS3777#.(#CM\L<,7 MUUR3B!<[?%'#%SOLL,,7.WCQ12)?>+'##E_L4,,77UQSS3777'.-%SOLL,,7 M.GSQQ1>))/+%%U_L\$7_#5_L\$4KUUQSS34[[/#%#E]<\\4.7^SPQ0X[?+'# M*3OL\,4.@^SPQ0Y?Z/!%(E]XL<,.-7RAPPZ#>+'##E_L\,47B'SQQ1T\L47.WRQ M0Q8[?+&#%P!I=>W:M6O79GW9H>-+C2^)KEV[=BW1%QTUONP8-.O:M6O7KEV[ M]F7'EQU?=GBY=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6L[L.SX MLB/1M6O7KEV[=NW:M6O7KEV[=NW:EQU?:GC9T>K:M40[=NSXLF/'EU;7KEV[ M=NW:M6NMONCXLF-'HFO7KEW[LF.'EQV#KEV[=NW:M6O7KEU+M&/'%QT[KEV[ M=NU+#2\[ONSXHF-'HFC7KEV[EFC'EQTUONSX[/#%#CM\<SPQ0Y?S'+--==<<\TU MUUQSS2!>[/#%#E]\<N7;MV[=JU:]>N7?NB8\>7'=>N74NTP\N.'?^MKEV[=NW:M6O7 MKEV[=NW+EQU8=ER[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEU#=^W:M1T[ M=GS9L2/+CB\[ONSXHN/+CB\[=GRIL6/'EQI?KEV[=NU:HAU?:NCX+'#%SNTN7;MV[=JU M:ZUV?-GAIN7;MV[=JU:]>N?=&QX\N.:]>N7;MV[=JU6:T&?=F19<>7 M&CN^U/BR8\>7'3NN7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>NH;MV[=J. M+SN^[$AT[=JU:]>N7;MV[=JU:]>N7;O_=NW:M6O7KEV[=BW1ER\[LB2Z=NW: MM6O7KEV[=NW:M6M?O.RH\>7:M6O7KEUK-6C'EQU>=NSXLF/'EQT[ONS8L>/+ MCFO7KEW;\65'C2_7KEV[=NW:M6O7KB6J\67'CE;7KEV[=NW:M6O7KEUKI6/' MCB]?KEV[=NW:M6O7KEV[=FU'EAT[OER[=NW:M6NMRGS1\67'CB\Z=GS9L>.+ M#E_LL,,7.EQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777/.% M#COL\$4BUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUR1"PPX[?('( M-==<<\TUUUQS_\TUUUQSS35?[+##%SM<<\TUUUSSA1<[?+'##E_L\(4..WRA MPQ>)S#+(#E_0\,4UUUQSS1+'##E\DTDHKLUQSS377>+'#%SOL<,TUUURS0Q8[?$'#-==< M<\TUUUQSS377)/+%#CM\T)7'/--==< M<\TUUUQSS3777//%%S1\L<,UUUR3R!N7;MV[5JB'32^[)AU[=JU:]>N7;MV M[=JU63NR[-#QY=JU:]>N7;MV[=JU:]=J?-FQ8\>U:]<&[?BRP\N.+ZVN7;MV M[=JU:]>N7?OR98>7'=>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]?07;MV M;<>7'3N^#+IV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;N6*(N.+SL27;MV M[=JU:]>N7;MV[=JU,CMV[/AR[=JU'3J^[-@QZ-JU:]>N7;MV[=JU:]>^[/BR MH\:U:]>N[=CQ9<>7_VO7KEV[=NW:M6O7$GW9L>-+JVO7KEV[=NW:M6O7KK7Z MLN/+CD'7KEV[=NW:M6O7KEV[MD-'EAU?KEUKM>.+CAT[#'+--==<<\TUUUQS MS3777//%%SO4\,4UUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS35?Z)#%#E\D#7'/--==<<\TUUUQSS3777//%%SM\4<,UU[2RPQ<[?*'#-==<<\TUUUQS MS3777'/--5]\L8,7.UQSS377U/#%#ECL<,TUUUQSS3777'/--8G4\,4.7_^T MTHL,.7^Q0QC777'/--==<<\TUUUQSS0Y?[/#%#M=< MT\H.7]3PQ1?77'/--==<<\TUUUQSS377?*'##E_L<,TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<+'#%SMX M<R0Q0X[#'+--==<<\TUUUQSS3777'/-#C5\L<,7UUQSS35>[+##%SM< M<\TUUUQSS3777'--(CM\H<,.K5QSS3777'/--=?_7'/--;-\L4,-7WQQS377 M7'/--==<<\TUUURS0PU?Z+##-=)7'/--==<<\TUUUQSS34`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`Y!KUZY=NW;MW+5KUZY=NW9M5J)$7[Y\^9(H M4;1KUZY=NW:MU9N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=HUUUQSS377 M7'/--==<<\TUUUQSS3777(/.-==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUR#SC77 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/-->A<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TU_]=<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--=>@<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSSC777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/-->A<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--?_77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777(/.-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUZ%QSS3777'/- M-==<A<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777',-.M=<=<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<@<\TUU\B`0``'!&#% M-=?_7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS14''"#``8%<<\TUUUQSS36LL,(**XA$<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUZ%QS MS3777'/--==<<\TU,@2`P`$"R'#--=<`Y-JU:]>N7;MV_^W:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O7KEV[=NU:(`0!#@3H@<\TUUUQSS3777'/-_S77L-+%%5;( M<$4@K%QSS3777'/--==<<\TUUUQSS377L!*(%3)$(4,@>[!RS3777'/--==< M<\TUUP0BP`$F'!#(-==<@\XUUUQSS3777'/--==<<\TUUUQSS3777'/--=>P M$L@55LAP11>F7(/.-==<<\TUUUQSS3777'/--==N78-R`$$`!"RN7;MV+1""`P$.L+IVC965``<"K`B` M(,"!`S)87;MV[=J5`P<$'&!Q[=JU:]>N7;MV[=JU:]>NF3H0X$``%M>N7;MV M[=JU+BP.!#B`(,"!``A6!)IU[=JU:__7KEV[=NT:*RL'!!Q`$.!`@`,'`K"P M$NW:M6NL#@@X(.!`@`,'`AQ`$`!!@`/7K@4Z(."``%;7KET+=.!`@`/7KET3 MQ.)`@`,(`AQ8$>"`E5;7KEV[=NW:M6O7KEV;%6B%@`,(`JP(<.``"T'7K@42 M<$!`@&O7KJ&[=NV:#`$'`ARPP M@$``!Y0@PS777'--(`<<(,`*5@2`P`$!',""#%?(L,(!!P1P0``KS'#--==T M$<`!`:S``CK77'/--==<<\TUUUQS#2L('"#``2Q<<\TUUUP1``(!!'!```?( M<(4,+!QP@``'"'#``:9<<\TUUUQQ0``'!(#``0>P8,45,K!P@``''!#``0>P MPDH``1P0P`$'"'#``0$<$,`!!P1PS35=(/\0P`$'L'+--==T<8``!QRPQP$" M'!```BS(<(4,!P1PP`$"K!#`%==<@\XUUUPCR`$!('!```<NR3@0X``"%M>N7;NV!T&``P$0!#@0(!"K:]>N M7;LF"$&``P@"'&!U[5JK`P@"(#C`ZMJU:]>N7;MV[=HU=%<.!#@00-"U:]<$ M'3@0X,`!&8*N7;MV[1JK*P<"'#@@X,"L:]=F!3AP0,"!%8*N7;MV[=HU5C(. M!$!P0("56:Q8L6)U)<`*!`&NL&+%2A"K:]<"!3@@X`"K:]>N[3D0`$&``P$. M(`C$ZMJU:]>N!4+_$.!```0!KEV[=NU:JQ4(`AP(<.`*JVO7KEV[QDI&@`,' M!!P0<"#`M6O7T%V[=HT%BP,"#LBX=NW:M2X'`B`(<.```E;7KEV[=NW:M6NL M$!P(<$!`EVO7KK$X<"#``4'77'/--==<<\TUUUQS#0L'(!#``==N70L4`,$!`0=87;MV[=JU M:]>N7;MV[1J+`P$0!+AV[=HU*P<"'!`0Z-JU:]>N7;MV[1H+`0<.'+AV[9J@ M%0(.'+AR[=JU:]>N7;MV[=JU:]>N!4!P(`"+:U<0!$`0@,6U:]>NH;MV[=JU M:]=8L4+$BA6K:]>N70L4`$$`!%VN7;MV[=JU:X$.!#@0`-&U:]?V(`B`X`"" M:]>N7;MV[=JU:]>N7;MVX$"``S*N7;NVXH"``P<$7;MV[=JU:]>N7;MV[=JU M*P<$'!!P`-VU:^BN7;O&`L$!`0>L7+MV[5H7!`$.'&!Q[=JU:]>N7;MV[=JU M_VO76""P0@`'7'/--=<@$L`!"!S`PC777'/--==<T$L@!!P1PP`$LL((..M=< M<\TUUUQSS3777'/--==<<\TUUW0AP`$K!!#(-==<<\TUUUQSA0`'!(``*]=< M=<<\TUUUQSS3777!,``@<(8,4UU[`2``('!,#"-==< M<\TUUUQSS3777'/--=>PP$,`!`1S`RC77 M7'/--==@$@,`!`AQPS377 MH'/--=?((,`!!P0@PS777'--%P@$<$``@5QSS3777'/--==<<\TUUUS#P@$! M''#`-==<<\TU5QP@P`$!=''_S3777'/--=>P<$``![!PS377M'+``0&L@``4 M,ES!@A4R6"&#%2Q8P8(5,D#!0@`'"'!`(-<$$L`!!P2`P`$!''``"U8$PLHU MUUQSS3777'/--==<Z'!!P(,`!`0<$'#@@ MX(``*X%:7;MV[=JU:]>N[3EP(,"!+M>N7;MV[=JU0"40!#C`ZMJU:UT0!$`0 M@-6U:]>N7;MV[=JU:]>N70MPX(``&=?0L3APH,2!+M>N7;MV[=JU:]>N7;MV M[=HU&0$.(`AP[=HU=->N76.!X$"``S*N7;MVKP M$@`"`1R`0``(!(#``0$<<(``!P1P0``('!#``0$@<``+Z/]<!7!%(%X%<$4@7@5P12!=[=!%(%WL(N7;MV[=JU:]>N'0APX`"+:]>N'`APX,"5:]>N7;MV[=JU:]>N M7;MV#5T`!`$0'$!W[1JZ:]>NL3APX$``5EQSS3777('``0$<$,@UUUQSS377 M7'/--==<<\TU+"!P@``'7'/--==<<\TU@1P0``(!=''--=>P<$``!UQQS377 M7'/--0BL(,`!!UQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUPCR`$(!'!```<(QR`0`D'=''--==<<\TUUP1R``(!',#*-==<$\@!"`1P@"#77'/--==<<\TU MUUQSS377'!#`_P$'L'#--8@$<$``!QQPS3777'/--==<<\TUUUQSS357'"#` M"@(<<,TUUZ!SS377R(!```<$(,,UUUQS31<"'!#``8%<<\TUUUQSS3777'/- M-==UUQSS3777'/--==<<\TUUUQCQ0$('!!`(`@<<$``5UQSS3777'/- M-==<<\TUUUQSQ0$!'%""#-=<QR`0``'L'+--==T<4``!R#`RC777'/--==<<\TUUUQSS34!('!`"3)<<\TU M@AR`0``'''`%.M=<<\TUUUQSS377L(+``0$<(,`!`:!SS3777'/--58$<$`` M"+!PS3777!/(`0$<_Q!`%]=<<\TUUUQSS3777'/--==8$<`!"`1PS3777'/- M-==<7`@0,'#APP<0#!M6O7KEV[=LU*@`,!#K"X=NW:M4`!#AP($.C: MM6O7KEV[=NW:M6O7KEDY$.!`@&O7KEV[=NW:M6O_UV0(."#@P($`!UA=NW;M MVK5KUZY=NW:-Q8$`!P0<$+!B1I=`5ZP$.'`@P`$!!ZY=NW;MRH$#`0X$.!#` MRI5`@;I8$7`@P($`!PX$NG;MVC56`@X(.(`@P($#`@YW:M6O7KEV[=HV5C`,!#@0X$.#`M6M7#@0X M$(#5M6O7N@0X$.``JVO7KEV[=NW:M6O7KEV[%N!`@`,LKEV[=NW:M6O7K@5B M<2#`@0`!#@1@T>7:M6M7`B`(<.#:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[ M=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[ M=NW:M6O7KEV[=NW:M6O76`6Z(H.%#!96NK"Z=NW:M6O7KEV[=NW:M6O76`7: M(X.%#!8RK@1B=>W:M6O7KEV[_W;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;--==<<\TUUUQSS377S,)* M(%T$@@@KUUQSS3776'%```@<<,TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<__--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS34'!'!``#*@<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/_S3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQCR@$"'("`%==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777`.0:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV_^W:M6O7KEV[=NW:M6O7KEV3(>!```2L MKEV[=NW:M6O7KEV[=NV:C`,!#@00=.W:M6O7KEU+].7+ET%?KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW+ET%?OER[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:-==<<\TUUUQSS3777'/--==<N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N76-UX("` M`P$.(&!Q)5"@0"P.(`AP0,`!`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`Y!KUW;L^++#RY=$ MUZY=NW;M6J(O.[[LV($ET;5KK;SL^++#R[5KUZY=NW;MVK5$.W3L^%+CRXYK MUZY=NW;MVK5KB7;L^+*CU;5$7W;4^+*C3+1KUZY=NW8MT9<=.[[4V-'JVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW8-'3ITZ-"ANW;MVK4O_SJ^[/`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``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`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``$'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT &Z`("`@`[ ` end GRAPHIC 12 f10k022912_10k004.gif IMAGE begin 644 f10k022912_10k004.gif M1TE&.#EA<`)3`/<`````````,P``9@``F0``S```_P`S```S,P`S9@`SF0`S MS``S_P!F``!F,P!F9@!FF0!FS`!F_P"9``"9,P"99@"9F0"9S`"9_P#,``#, M,P#,9@#,F0#,S`#,_P#_``#_,P#_9@#_F0#_S`#__S,``#,`,S,`9C,`F3,` MS#,`_S,S`#,S,S,S9C,SF3,SS#,S_S-F`#-F,S-F9C-FF3-FS#-F_S.9`#.9 M,S.99C.9F3.9S#.9_S/,`#/,,S/,9C/,F3/,S#/,_S/_`#/_,S/_9C/_F3/_ MS#/__V8``&8`,V8`9F8`F68`S&8`_V8S`&8S,V8S9F8SF68SS&8S_V9F`&9F M,V9F9F9FF69FS&9F_V:9`&:9,V:99F:9F6:9S&:9_V;,`&;,,V;,9F;,F6;, MS&;,_V;_`&;_,V;_9F;_F6;_S&;__YD``)D`,YD`9ID`F9D`S)D`_YDS`)DS M,YDS9IDSF9DSS)DS_YEF`)EF,YEF9IEFF9EFS)EF_YF9`)F9,YF99IF9F9F9 MS)F9_YG,`)G,,YG,9IG,F9G,S)G,_YG_`)G_,YG_9IG_F9G_S)G__\P``,P` M,\P`9LP`FN7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV#=VU:]>N7;MV[=JY M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]?07;MV[=JU:]>N74.'#AVZ:]>N7;N&#MVU M:]>N7;MV[=JU:]>N7?^[=NW:M6O7T*%#=^[:M6O7KEV[=NW:M6O7KEV[=NW: MM6O77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3G77'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUS_ M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUR##CKHH(,..NB@@PXZZ*"##CKHH'/--==<_W/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<@\XUUUQSS377 M7',-.NB@<\TUUUQSS34`N7;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;M MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NX;NVK5KUZY=NW;M&CITZ-"ANW;M MVK5KYZY=NW;MVK5KUZY=N_]V[=JU:]>N7;MV[1HZ=.BN7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N77/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS37_UUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377H(,..NB@ M@PXZZ*"##CKHH'/.-==<<\TUUUQSS3777'/--==<<\TU_]=<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TYUUQSS3777'/-->A<<\TUZ%QSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS377H(/.-==<<\TUUUQSS37HH(,..NB<<\TUUUR#SC77 M7'/--==<<\TUUUQSS3777'/--?_77'/-->B@@\XUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUP#DVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KU]"ANW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK7_:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;N&#MVU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MVS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777(,..NB@@PXZZ*"##CKHH(,..M=< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS_\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<=<<\TUUUQSS3777',-.NB@@\XUUUQSS37HH'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQS#3KHH'/--==<<__--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777(,..NA<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<N7;MV[=HUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUZ%QSS3777(/.-==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--=>@<\TUUUQSS377 M7'/-->B@@\XYUUQSS3777(/..==<<\TUUUQSS3777'/--==<<\TUUUQSS37H MH(/.-==<<\TUUUQSS3777'/--==<<\TUU_]<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/-->B<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<@PXZ MYUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--=?_7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS37H7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<A<<\TUUUQSS3777'/--==<@\XUUUQSS3777',-.NB@<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS?\UUUQSS3777'/--==<<\TU MUZ!SS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<B@@\XYUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUZ*"##CKHH(,..NB@@PXZZ%QSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<_W/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS377H'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUZ"#SC777'/--==<<\TUUZ"# M#CK77'/--==<<\TUUUQSS3777'/--==<<\TUYUQSS3777'/--=<`!!TZ=->N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:__7KEV[=NW:M6O7 MKEV[=N[:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=N[:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KJ%#A^[:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=LTUUUQSS37_Z*"#SC777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS#3KHH(,. M.NB@@PXZZ*!SS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TU_]=<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377H(/.-==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQS#3K77'/--==<<\TUUUQS#3K77'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--=>@@PXZZ%QSS3777'/--==<<\TUUUR# M#CKHH(,..NB@@PXZUUQSS3777'/--==<<\TUUUQSS3777'/--?_7H'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;O_A@X=NFO7KEV[=NW:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:-73HT*%#APX=.G3HT*%#A^[: M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQS_\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS377D`(```!@@TT"UUSCS`[77'/--=>@<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS377G'/--==<<\TUUUQSS377G'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TS)````#;88`/``]=<8PT=CUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUZ%QSS3777'/--==<<__--==< M<\TUUUSS#!(``````#I<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUB"1R#777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/.-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS377H(/_#CK77'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQS#4"N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>NG4.'#ATZ=.C0H4.' M#ATZ=->N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU_VO7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[ M=NW:M6O7GB$!H./:M6O6D````$#'M6O7KJ&[=NW:M6O77'/--==<<\TUZ*"# M#CKHH(,..NB@@PXZZ%QSS3777'/--==<<\TUUZ"##CKHH(,..M=<<\TUUUQS MS37HH(,..M=<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TQ```` M``377'/--<^0``````20R#777'/--==<<\TUUUQSS37HH'/--==<<\TUUUQS MS3777'/--==<<\TUUZ!SS3777'/--==<<\TUUUQSS3777&,-'@#H<(TU>/\` M`,`#UZ!SS3777'/--==<<\TUUUQSS3777'/--==<<\TUUZ!#"@`)S'+--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777',-.NA< M<\TUUUQSS3777'/-->B@@PXZZ*"##CKHH(,..NA<<\TUUUQSS3777'/--==< M<\TUUUQSS377H(,..NB@@PXZZ*"##CKHH(,..NB@@PXZUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777',-.NB@<\TUUUQSS3777'/--=?_7'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777',-.NB@@PXZZ*"##CKH MH(,..M=<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS34` MN7;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5K_]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N77N&!(`.=->N7;MV;10``%^N7;MV[=RU:]>N7;MV[=JU:]>N M7;N&#ATZ=.C0H4.'#ATZ=.BN7;MV[=JU:]>N7;MV[1HZ=.C07;MV[=JU:]>N M7;N&#ATZ=->N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]:0```0(-&U:]>N M7;MV;10```(>7;MV[=JU:]>N7;MV[=JU:^C07;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=RU:]>N7;MV[=JU:]>N77/--9P`(,`LUUSS#`D``*`#.NA<<\TUUUQS MS?\UUUQSS3777'/--==<<\TUUUQSC35R`!#`(]=<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<@PXZUUQSS3777'/--==< MB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"#SC777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUZ%QSS3777'/--==<<\TUUUQSS3777'/--==<<\W_-==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<@PXZZ*"##CKHH(,..NB<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/-_S777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3776(,'``$D@LXUUUQSS377C`*`#M=<@\XUUUQSS3777'/--==<<\TU MUUR##CKHH(,..NB@@PXZZ*"#SC777'/--==<<\TUUP#DVK5KZ-"A0W?MVK5K MUZY=NW;M&CITZ-!=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KU]!90P(``(`R MUZY=NW;MVK5KUYP!")#HVK5KUZY=NW;MVK5KUZY=NX8.W;5KUZY=NW;M&CIT MZ-!=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVC5G```DF'7MVC5.``!`N';MVK5K MUZY=N_]V[=JU:]>N7;MV[=JU:]>N77,&````"->N7;MV[=JU:]>N7;MV[=JU M:^C07;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV#1TZ M=.C0H4.'[MJU:]>N7;MV[=JU:]>N7;MV[=JU:]>N74.'#ATZ=.C0H4.'#ATZ M=.C0H;MVS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSSC777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUS_<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<@PXZZ*"##CKHH(,..NB@@PXZUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<_W/--==<<\TUUUQSS3777'/-,R0`($`B MUUQSS377H'.--4AX<@@PXZ MZ%QSS3777'/--==<<\TUUUQSS3777'/--==<@@PXZ MZ%QSS3777'/--==<<\TUUUQSS3777'/--==P`@```LQRS377<`(``#J@@PXZ MUUQSS3777/]SS3777'/--==<`Y!KUZY=NW;M&B<````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`#8``%#&-==<<\TUUUQSS3777&.-$H]<<\TU MUUQSS3777'/--==<B@@PXZZ%QSS3777'/--==<<\TUUUQSS3777'/--==<@@PXZZ*"#SC777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377H'/- M-==<@@PXZZ%QSS3777(,..NB@<\TUUUQSS3777'/--==<A<<\TUUUQSS3777'/- M->A<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/_ MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--0"Y=NW:M6O7 MSJ%#APX=.G3HT*%#AP[=M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:-73H MT*&[=NW:M6O7KEV[=NV:-20```````"`#G37KEV[_W;MVK5KZ*Y=NW;MVK5K MUZY=NW;MVC5TZ-"ANW;MVK5KZ-"A0W?MVK5KUZY=NW;MVK5KU]"A0X?NVK5K MU]!=NW;MVC5TZ-"ANW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUYP!````0()9 MUZY=NW;MVK5KUZY=<\TUUUQS#3KHH'/--==<<\TUUUQS#3KHH'/--==<<\TU MUUR##CKHH'/--==<<\TUUUQSS3777'/--==<<\TUUUQS#2D```"``%4`@$T9 MUUQS#3KHH'/--==<<\TUUUQSS3777'/--==<<\TUUUB#!!E(``````"4<@<\TUUUQSS3777'/--=>@<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-=?_7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377H(,..NB@@PXZZ*"# M#CKHH'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUR# M#CKHH(,..NA<<\TUUUQSS3777#,*````!````````-"!_^[:M6O7KEV[=NW: MM6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[A@X=.G3HKEV[=NW:M6O7KEV[=NW: MM6O7T%V[=NW:M6O7KEV[A@X=.G37KEV[=NW:M6O7KEV[=NW:M6O7KEV[Q@D` M````+%R[=NW:M6O7KEV[=NW:M6O7KEU#APX=.G37KEV[=NW:M6O7KEU#=^W: MM6O7KJ%#APX=.G37KEV[=NW:M6O7KEV[=NW:M6O7KEU[1@(````)KEV[=NW: MM6OHT*%#=^W:M6O7KEV[=NW:M6O7KEV[=FW4@VN<``````#"M6O7KEV[=NW: MM6O7KEV[=NT:NFO7KEV[=NW:M?]KU]!=NW;MVK5KUZY=NW;MVK5KUZY=NW;- M-==<<\TUUUQS#3KHH(,..NA<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<@PXZZ%QS#3KHH(,..NB@@\XUUUR#SC777'/--==<@\XUUUQSS3777'/- M-==<<\TUZ*!SS3777'/--==<<\TUZ*!SS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\W_-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/-->B@@PXZZ*"##CKHH(/.-==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS#3KHH(,..NB<<\TUUUQS MS3777'/--==P`@````````````!`&==<<\TUUUQSS3776(/$_P[77'/--=>, M`@```&"##3;8```!.M>@,PH````````07'/--==N7;MV[=JU:]>N7;MV[9HS;-@```"P M`]VU:];D``````"`!+.N7;MV[=JU:]>N7;MV[=JU:W)T7'M&`@`V``(27;MV M[=JU:]>N/4,"`$"`1\^\7+MV[1D2`/\``CQZYN7:M6O7.`$```````C7KEV[ M=NW:-6M(`&##AJT,NE*S1@$```````C7KEV[=LT:$AW7KEV[=LT9`&S8```` M````````OC@#````-FS8L`$`$.#1M6O/D```$.#1,R_7KEV[=NW:M6O7KHT" M```````0KEV[=NW:*````````.':M6O7KEV[=NW:-6M(`&##AJT,NE*SKEV[ M=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:-==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUS_<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/-->B@@PXZZ*"##CKHH(,..NB@<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777(,..NB@@PXZUUQSS3777'/--==<<\TUHP`` M````````````\,`LUUQSS3777'.-,P`\,,LUUUQSS376X`$``(E<_V,-$@`` M4,8UUUB#!``"/'+--==<<\TUUUS#"0``)'+--=N M7;MV#9TU)``$)+IV[=JU:]>N64,"0,"C:]>N7;MV[=JU:];P``!0YMJU:YP` M")AU[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;O_=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEU#APX=.G3HT*%#APX=NFO7KEV[=NW:M6O7KEV[=@T=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ%QSS3777'/--==<<\TUUUQSC35R`````````````$!P MS3777'/--=;@`4``B5QSS3777'.-'```4,8UUUC#!@`!)'*--4@`$$`B_]=< M<\TUUUQSS36<``!`&==<<\TUI"1RS3776",'``$D```````/S'+--==8@X0`B5QSS3777'/--==< M<\TUUUQSS3777,,)!-=<N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV#1TZ=.C0H4.'#ATZ=.C0H;MV[=JU:]>N7;MV[=HU=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#AVZ<^BN7;MV[=JU:]>N7;MV[=JU:];D``````````#*7+MV[=JU M9T@``(!P[=JU:]>LR0$`H,RU:]=&`0``X9HU)``$)+IV[=JU:]>N7>,$`$"9 M_VO/$EUSS3777'.--7(`$$`BUUQCC1P`!/#(-==<<\TUUUQSS3777'/--==< MH'/--==<<\TUUUQSS375(`%``(E<<\TUUUQSS376 M(`&``(E<<\TUUUQSS377C`(``%Y<<\TUUUQSS36>S'+--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/_S3777'/--==<<\TUUUQSS3777'/--==<<\TU MYZ"##CKHH(,..NB@@PXZZ%QSS3777'/--==<N7;N&!X"`1]>N64,"(,&L:]>N7;MV[=JU:]>N7;MV M[=JU:Z,`````(,&L:]>N7;MV[=HH``"P`0"08-:U:]:0`!#PZ-JU:]N7;MV[=JU:]>L(0$`(,&L:]>ND0(` M`````%ZN6<.38-:U:]>N7;MV[=JU:]>N7;MV[=JU8PEF7;MVS37'``````!` M<,TUUUQSS36<``````$D```````_P!0QC777'/--==8(P<``22"#CJ<`"#`+-=<<\TUUUQSS3777'/- M-==<`Y!KUZY=>T8"`````F9=NW;MVK5KUZPA`0```(`RUZY=LX8$P(!9UZY= MN\8)&P```+`!T('NVK5KG+`!````&P`=Z*Y=NW;MVK5KUZY=NS8*`````F9= MNW;-FAP``````*`#F8!9UZY=NW;MVK5KUZY=NW;MVK5KUZPA*7/MVK5KUYZ1 M````@(!$Z*Y=NW;-FAP`````$)`(W;5KUN0`````0(!$UZHA`1`@T;5KUZY= M>T8"@(!#2``(>'3MVK5KUZY=NW;M6C4D``3,NG;MVC5K2F:-`O\`H,RU:]>N M7;MVS1H2;`)F7;MV[=JU:YP``````$"9:]>N7;,F!P`````")+IV[=JU:]>N M7;MV[1HZ:T@`!'AT[=JU:]>N7:N&!$``CUQSS3777'/--<^0`(``CUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<@P[_.NB@@PXZZ*"##CKH7'/--==<````0`")7'/- M-=:P`8``CUQSS377<`(``&5<```0!G7<`(``&5<```0!G77'/- M-==<<\TUUY`"``````!``K.@@PXZZ#@#``#88`,```+,@LXS)21RS3777'/- M-==<<\TUUS@CP"S77'/--==<A<AP4L8UUUQC#1(`/##+-==<<\TUUB`!@`"S7'/--==<N69,#($"B:]>>D0``0,N7;MV[=JU:]>N7;O&_PD;```ZKEV[=NT9$@#8L"68=>W:-6M( M``B8=>W:M6N<```H@\Z:'```(%R[Q@D`@#+HK,D!``#"M6O7KEV[=NW:M6O7 MK,D!```;-FP`````$""1-238L`$```"`CFO7KEV[=NW:M6O7KCTC`2#!K&O7 MKEV[=NW:M6W:-72C M``"`<.W:M6O7K"$!(-==<<\TUUW`"```ZH(,..L^0D(`L2`"0P"S77$,* M`&540P(``/^4<@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NC_H(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ%QSS3777'/--==<<\TUUS@#P377/$,"-MA@@PTV95QSS3776(,$-MA@ M4\8UUB"!#3;88)/`*-A@@PTVV&"##38Z7'/--:-@@PTVV&"##3;88!-`(LY@ M@PTVV&"##3;88(,-!-=N7;,F!QLV M;-BP82MS[=JU:YRP8<.LV;-BP0:B&Y9HS;-BP!4AT[9JU*]><8<.&+4"B M:]>N7;OF#!LV;-BPZ;AV[=JU:]>N.<.LV;!"N7;LV"ALV;-BP.4""#1NV M,M>L(<&NV!+.N69.##1LV;-@2S+IVS1DV;-BP8<.LV;!"J8;GF#!LV M;`$27;,F!P``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`<,TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<_W/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS2@0 M7'/--==<<\TUUUQSS3777/]SS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUP#DVK5KUZY=NW;MVK5KUZY=NW;MVK5KU]"A0X<.'3ITZ-"A0X?NVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;_[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:^BN7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]?0 M69,CX-&U:]>N7;MV[=JU:]>N7;MVS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU_]=<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS36N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[=HUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<N7;MV[=JU:]=<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUR##CKHH(,..NB@@PXZ MZ*"##CK77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--=?_7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377_UQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--0"Y=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[ M=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[ M=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=O_MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZZA0X<.'3ITZ-"A0X<.W;5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\W_-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M_S777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS?\UUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377`.3:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[A@X=.G3HT*%#APX=.G3H MT%V[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O_UZY=NW;MVK5KUZY=NW8-W;5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<_W/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777/]SS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777',-.NB@@PXZZ*"##CKHH(/.-==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS3777`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`Y!KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;M MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;M MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW8- MW;5KUZY=NW;MVK5KUZZANW;MVK5KUZY=NW;MVK5KUZY=NW;_[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV#=VU:]>N7;MV M[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=HUUZ"##CK7 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<@\XUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<_W/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS#3KH7'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQS#3K77'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777/]SS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777',-.NB@@PXZZ*!SS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/. M-==<<\TUUUQSS3777'/-.==<<\TUUUQSS3777'/--==<<\TUUUS_<\TUUUQS MS3777',-0*Y=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KYZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=0X<.'3ITZ-"A M0W?NVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KYZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5K_]>N7;MV[=JU:]>N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=RU:]=<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS377G'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--?_77'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--=>@@PXZZ*"##CK77'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/-->B@<\TUUUQSS3777'/- M-==<@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CK_Z*"# M#CKHH(,..NB@@\XUUUQSS3777'/--==<<\TUUUQSS3777',-.NB@@PXZZ*"# MSC777'/--==<<\TUUZ"##CKHH(,..NB@@PXZZ%QSS3777'/--==<<\TUUUQS MS3777'/--=>@@PXZZ*"##CKHH(,..M=<<\TUUUQSS3777(,..NB@@PXZZ*"# M#CKHH'/--==<<\TUUUQSS3777'/--==<<\TUUUR##CKHH(,..@!!APX=.G3H MT*%#APX=.G3HT*%#AP[=M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEU#APX=.G3H MT*%#AP[=M6O7KEV[=NW:M6O7KJ&[=NW:M6O7_ZY=NW;MVK5KUZY=NW8-'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ*Y=NW;MVK5KU]!=NW;MVK5KUZY=NW;MVK5K MUZY=NW;MVK5KUZY=NW;MVK5KUZY=NX8.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.W;5KUZY=NW;MVK5KUZY=NW;MVC5TZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITUZY=<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TU MUUQSS3777'/--==<<__--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUZ*"##CKH7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--=>@@\XUUUQSS3777'/--==<B@@PXZZ*"##CK77'/--==<<\TUUUR# M#CKHH(,..NB@@PXZZ*!SS3777'/--==<<\TUUUQSS3777'/--==<@PXZZ*"# M#CKHH(,..NA<<\TUUUQSS3777'/--=>@@PXZZ*"##CKHH(/.-==<<\TUUUQS MS3777'/--==<<\TUUUQS#3KHH(,..NB@@\XUUUQSS3777',-.NB@@PXZZ*"# M#CK77'/--==<<\TUUUQSS3777'/--==<<\TUUZ"##CKHH(,..NB@@PXZUUQS MS3777'/--==<<\TUZ%QSS3777'/--==<<\TUUUQS_\TUUUQS#3KHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@\XUUUQSS3777',-.M=<<\TUUUQSS3777'/--==< M<\TUUUQSS3777'/--==<<\TUUUQSS377`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`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`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`Q!TZ-"A0X<.W;5KUZY=NW;MVC5TZ-!=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY= MNW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KUZY=NW;MVK5KU_^N7;MV[=JU:]>N M7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MVS9H<```` M`````$"9:];D`````!LV;`"\R`$```````(27;MV[=JU40````#@Y9HU.0`` M``````"`,M=(`0``````````?+EV[=JU:]>NC0(`````+]>N<0(````````` MZ$!W[9HU.0````#P0`X```(2H;O&"0````````````"`!==<8XT<`````#;8 M8`/`%];(`0``````@`")6",'````@`TVV`#PA35R``"``(F@"$'```(D`@ZUW`"```````````````` M`'QQS3777&.-'```````````0!G6R`$```!@@PTV`'QQS377<`(```!X80T6 MUU@C!P``````!-60`(``L@ARS37'````````````````````8(,--@!\88T< M``````````!`&==8(P<```"`#3;8`+##-9P```````````377'/--==8(P<` M```````")&*-'```````$%S#"0``0#`*`-@```````#@A1P``````#J@<\TU MUL@!``````#!-==<\PP)`&`CP"S//'+--==<<\TUUU1#0AG77'/--==<<\TS M)`"`C0"S_SSSR#77/$,"```(,,LSB:!S#2G88`,``%Y<<\TUUL@!``````#! M-9P````````@0"+H7,,)`````````````````."%'```````#\@!```")(+. M-9P````$UUS#"0```."%-5A<<\TUUUS#"0```(`--@``H(,<```````/R`$` M`````````)1Q#2<`````!-=<<\TUUW`"````0'#--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/- M-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUU_]<<\TUUUQS MS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777',-0*Y=NW;MVK5K MUZX]`Y!@UC5G``"4N7;-&38!LZY=##KFC,` M`F9=N_;,R[5KUZY=N/0.08-8U9P``E+GF#("`6=>N.=-QS1H2`#JN71L%X,&U:]><`0B0R!H; M'=>L(8%P[=JH,M=4@T0`B5SCC`[.8"/`+-=0`L`#LUQSS37.`!!`(M=<U9 MHFO.``1(=,V:'``)KEU#!F#`K&OHKEV[]NS_$`D`#V9=>Y;HVK5KST@(2'3M MVK5KUZY=NW;-&8`'UZY=DP-`QS5G``;,NG;M&CITG`!`N';MVC5K6*Y=N_:, MA(!'STA`0(?.&I9KUZY=N_:,A(!$UZY=7'/--=>,@HT`LS@#0`*S7.,,``+,7'/--=<\DX@S````P375#'*-,]@(\,@UUY`" M0`")7/,,``+,\HP7UUQSS3.).`,``!!<\TPBUUS_KEV[=LT9``&/KETC!2!`HFO7KEUS!B#!K&MR`.BX MY@Q`@$37KEU[ENC:-6M(`B2ZY@Q`@$3.``AX=.W:M6O7KCU#$B#1-6M(`#RX M=NW:M6O7KEV[=NW:M6O/$"$!H./:M6O6D`!X<.W:M6O7KEE#`@#"M6O7KEV[ M9@T)`"_7KEV[-@J`@%G7_ZXY`Q`@T;5KZ)XENO8LD3,``"!<>Y;HVK5KU4@$ M2'3MVK5KU4@$2'3MVK-$S@``@'#M6:)J2`#HN';MVC5TUZY=NW;MVK5G``3, MJH;EVK5KU9`$2'0-G3,`"69=,`@``7E0#D$37 MKEU[AD3`HVO7KEU[AB3`HVO7GB6Z-@H``"_/$B$#`"#1M6O7KEU#=^W:M6O7 MKB$#````-@C7KEU[1B+`HVO7D`$```"`@%G7KEU[EL@9``!EKCU+]`R)@$?7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7KEV[=NW:M6O7 MKEU[!O_@P2H2`"!@\D\@USR1R_\TUG```0!>#7'/--<^0$$`BUUQSS375 MD"!`(M=<\TPBUUS#"0``=)&(,P``4,8UUUR##CKH7'/--==<N7;MV[=JU M:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU:]>N7;MV[=JU M:]>N7;MV[?^:,P`)KCD#`*#,M6O7G`$0,.O:M6O7KCD#D.#:M6O7KEVSA@2` MEVO7KET;!6#`+&<`$EQS!@!`F6O7KEU[1B)`HFO7KEV[=NV:-20`O%R[=NW: M*``#9CG#)F#6M6O7KEV[=NW:M6=(`B1"=^U9HFO7K,D!`"#1-60``CRZ=FT4 M``&/KB$#(M6O7KEV[Y@Q`@FO7KEV[=LT9``&SKEV[=NW:M6>)KEVS)@<` M@$37D`$(\.C:M5$`!#RZA@R`@%G7KEV[=NU9HFO7K,D!`*#,M6O7GI$(D.C: MM6O77'/--==''--==<,PH``\QRS37.`"!`(M=< M<\TSB:#S3"+77&.-'```4,8UUUSS#`D!_R1RS3777/,,$@$D@LXUSR1RS376 MR`$``&4\0P(`95QC#1(```"``+-<<\TUUS@#@`"S7'/--==<\PP2`22"SC7. M`)#`-7/,,``+,<@TZ`$&'#ATZ=.C0/2,A(-&U:\\27;MVS1H;`&6N.0,@ M(-&U:YP`))AU[1D``;.N7;MFK=4U9P`>S+IV[=JU:\\`")AU[=HU:ZVN/4MT M[=HU:VP`E+GF#("`1->N<0*08-:U9P`$S+IV[9JU5L\27;MVS1H2`&6N7;M6 M#8F`1]>N7;MV[=JU:]><`7@PZQHG``)F77,&0,"L:]>N09,E!P"$:]?_KG$" MD-73/2`AX]*S%K&O7G`$H<^W:M6O5D`AX=.W:M6<`!,RZ=NV:M5;7G`%X M,.L:)P`"9EV[]@R`@%G7KEVSUNJ:,P`"$EV[Q@E`@EG7KEV[Y@S`@UG7KEV[ M=JT:B0")KEU#1RK1M6O6D`A(=.T:,@`#5`$0,.O:M6O'RJ#S#`D"/'+--9P` M(,`LUUQSS370S'+--==<8XT@UUQSS3$`!)#(-==P`H``LUQSS3770#,+)P`( M,,LUUUQSS3.SD`+``[-<<\TU>`#@Q3777%,-"0$DB@@PXZSY`@0"+77.,,``_,<@TG``@P"SK/ M)'*--4@`(,`LZ#Q#@@"/7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..LX`D,`LUUB#!``0 M7'.-,P`$D`@ZZ%BCQ/\LS@"0P"SHH(,..NB@8XT<`'QQS36C`)#`+.@X`T`" MLUQC#1(`0(#.-=<\0T(`B5QSS3777'/--==8(P<`7UQSS2@`)#`+.LX`(,`L MZ*"##CKHH(,..N@X`T``CUR#CC-E7'/--=<\0T(9US@#0`")H$,*``+,@@PXZS@"0P"S76(,$`!!N77M&(D"B:^C0.0,0(!$Z=-:4 MS+KF#$""6=>L(0$`X=HU9P`")$*'SIJ26=><`0B0"!TI``)F7;MV[1HZ9P`2 MS$*'#ATZ=-;D`+!P[5JU*+/0H;.&)$`B=,](`(#@#$"`1.C0.<-6YIHS``$2 M7;MF30Z`!+/0H4,&X=JU:^C0=7IT[=HU:T@`0+AVS9H<``EFH4.'#,(U:W(` M))B%#ATR"->LR0'PY=JU40`2S$*'#ITU.0`L7+M6+NH4/G#$"`1]?0.2MS[=JU:\]()+IF_PT)@#+7KG$"`.':M6O7 MKEUS!D#`+'3HT*%#YPQ`@$?7T#D#D,`LUUB#!``07.-,&>B@PPD`$*"#CC,` M!)#(-==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS377 M7'/--==<<\TUUUQSS3777'/--==<<\TUUUQSS3777'/--=>@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..M;(@0TV``!0QC7.8(,--MA@@PTVV``````! MJ``````$D`@ZZ*"##CKHH/\S"C8```"`#NA8(P"`'```(UZY=N^:L_\RU:]N7;MVC1,V````Z$"'SIH<;````'@@!QLV``#*7'.L````2S'J&I(PU M.=BP`0```1TZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..O_HH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CK_Z*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ_^B@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,.0-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ/_0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.B@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(/_#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#_PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ&"##3;88(,--MA@@PTVV&"##3;88(,--MA@@PTVV&"# M#3;88(,--@#!A@T;-FS8L&'#A@T;-FS8L/]APX8-&S9LV+!APX8-&S9LV+!A MPX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!A MPX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!A MPX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!A MPX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!A MPX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!APX8-&S9LV+!A MPX8-&S9LV+!APX;_#1LV;-BP8<.LV;-BP88,--MA@@PTVV&"##3;88(,- M-MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,- M-MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,- M-MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,- M-MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,- M-MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;88(,--MA@@PTVV&"##3;8_V"# M#3;88(,--MA@@PTVV&"##3;88(,--MA@@PTVV&"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ/^@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH``0=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#AP[_'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M_SKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##O\ZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@P[_.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*`#$'3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3H_]"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3KHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH/^##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*#_@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##D#0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0_Z%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HH(,..O_HH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CK_Z*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZ_^B@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ M`$&'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#O\=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*&##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(/_#CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"#_PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@_\. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..N@`!!TZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C_T*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKH_Z"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ/^@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@`Q!TZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-#_H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,._SKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##O\ZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@P[_.NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,.0-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A M0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A M0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A M0X<.'3ITZ-"A0X<.'3ITZ-"A0X<._QTZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.B@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH/^##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*#_@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@_X,..NB@@PXZZ*"##CH`08<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3IT MZ-"A0X<.'3ITZ/_0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H8,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CK_Z*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ_^B@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH``0=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT/^A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(/_ M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"#_PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@_\..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*`#$'3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAP[_'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A M0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A M0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'3KHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"# M#CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH_Z"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ/^@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##D#0 MH4.'#AW_.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H MT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3H_]"A0X<.'3IT MZ-"A0X<.'3ITZ-"A0X<.'3ITZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##O\ZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@P[_.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ`$&'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ M=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0_Z%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX= M.G3HT*&##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@ M@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH/^##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*#_@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@_X,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..N@`!!TZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.' M#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#O\=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%# MAPX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APX=.G3HT*%#APXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKH MH(,..NB@@PXZZ*"##CK_Z*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ M_^B@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,. M.NB@`Q!TZ-"A0X<.'3ITZ-"A0X<.'3ITZ-"A0X<.'?\Z=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0H4.'#ATZ=.C0 MH4.'#ATZ=.C0H4.'#ATZ=.C`T*%#APX=.NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ MZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@PXZ @Z*"##CKHH(,..NB@@PXZZ*"##CKHH(,..NB@@TY``#L_ ` end XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; word-wrap: break-word; } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } ZIP 14 0001078782-12-001613-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001078782-12-001613-xbrl.zip M4$L#!!0````(`+MHS$"VDK;/B!T``.;*Z]?-GZR:[ML;W+Y=#6@`28K)**1;)-??]TS(VDD))!!@'9- MJE)KT$QW3T^_3X_X\=_/$\MXI"YGCOWNH%&K'QC4'C@FLT?O#AAWJMWN4:_: M./CW3W__OQ__4:T:U]0YLXCK/>9QX-8!BM6KO=:AM&M8HSGONN M90`*FY^8E+T[&'O>].3P$+^N<3JHC9S'0WAPV*PW&M5ZH]IJ'*CA0V:%PY^> MGFK3,7$GA-F/E'M`G$V?>&W@3'!FL]YL]M2\V!R!QG%',*C>.F0V]X@]H`&& M9\YBHY]:P=C&X7\^?;P?C.F$5.=F6OU#L738.C`09 MGK(7T._SZHB0:3AC2'A?C%8/4I@*&]IN-CJ+D,@1.DUF8M_4V.-#^?``]OEO M/^)B3KA@V1T=&H(/)V.7#M\=3)G-JL$VU9ZY>:`>>[,I?7?`V61JP:(.!1P0 MAI-S9^!/J.T]P'-CX-@>??;N$-)YHU%OU1O_53O^4Z->_>7'P^24.3BWU&6. M>6&;Y\1;#!"IK-:;U68O#C8&(81_"H],?'QID=%"N$-B<2I!QB:%H"YLCWFS M.SIBW'.)[5V3R6)*;W\^O?MT:EQ=_WIQ_W!U_<&XOOCMO@*?SVH23QK$!+HS MH,(EUI5MTN=?Z&PAOCIHQ1'L>KNC@T]`".&?^:Z+2V1\0*S?*7'S,+\J.-^5 M\+,@))?@3":.?>\Y@R_W8"`HO_$]U!*T7X9O,XE)/CJ(8;\"M,?UXP/#I`,V M@?V!KZXO#WXZ:ATW8*FQ52Y`DJ#GUN];;'!I.<2+T'^^/Y_'+4Q6`G==QZJ! M2B!!J^N>`3-&CKMXU^X!.(PU[NC4<=%L&K"6*;%G.J(8N"1_Y3:$\^\]XH'I M7X3S=\ICS$N%D$#SJV/YMD=<2.#CXQ,P'W-VI9O]C.DWU/"7=L:EYQ M[@,_\L//@#!G8R)!O81O%J\`K$PK;E\2LS.@2RNT'/[E[VG0M=D"OO(2)V>$ MCT]M$_^Y^--GC\2"*?S4.R.N.X,-^Y58/EU!F!O-5O?XQ\,7H2F8L`80UITC MK`>V;!VZ3CFG'E^?(Q+.2T'G65,:Y,'``47AMV1&^A956KG"(HZ.VIVFABH5 M[KJHTQ=Y%%_D(T&?#+H*$=`8TZC$. MY"3A(R-]9C%\O,*R>_76<2O"J0%;"4G&PN);FX7D%N))"@LTA2]>U3!IB%(` MKH4P?74O0*B%&JLN[ZC1U?0S"7!U;'ET^"TTG.6(%'U5[]N-?1C,7:1&QS31F\/X[;OV*7),1V[%@FQ)$8 M"GBS5=C>Z?0Z&MOG@:Z#,Q=;EJ#4C"O$/84L.A'8+,-0'#EY@J$741.WS^!4 M;UQ,6*@IS!F$T"(!U&CB9O!E3N=3@T0ZRQ]DX=L4B1GNJF`29%$F+*%2LR!.((1O'O>X"*B3T(BC(CBL7\R$/!2^J!J[&B&0ML`A: M5F5)%BUW$/;8_L+,+%%#6I#"!,!6P="L=_^[/$E:&\/+UC!D%K#2YKZ%]Z<7SE-I\49R_ MC)GM9CO:LR5H"B1I`=L;,07<,DGI7#I>F4NWKC.DG(OL=3VQ[[2;G98>",4! MKX-UP68<):*O@I%F++67?ZDW4XK*^VMPN-N.9?-SD-?"NX#'\=1R`VBS MJHXO6"[N`?,^.GP-_E83#(Y@KH9J`4L3Z7HAF/+5@#)071#7!M[R(-Y^3S@; M@`4Y9Y;OZ0%<9JR_C+D0\VLUR27X-D#;(D=:TSNJ7=E#YP)+5:W8V!7 M1IA?PPO$ET_/LQ'"URXE6""5_U[9B6.T=4+?V,'@4DR%TI4[2M@!6;G.4=>E M:Z5SQB4[VNXV.HLHS'G^6""Q^?+'TE"Z4;:"DF/3`OCT1V92\_WL,Z?FE1V& M2J<#B/N7'<@NLYS-7KO>C1F6G#@W0^HBF]M(VMS=4YK!U%:]"*;"^`&E)K]T MG8DF+;-SVE]#YYOU>J<=BQ@SD11%S9)TN[X#:C(Z0`K@#58ML8GW9JA5[U;? MKD:ST\Q@4"JF0NG*9XUW0-,&>)6AI)?,AGD%6=M6L]-K+[4+*2@W0VE^O2P% MI1G.MA">IC<)RH[*I`-?8_]S-$RFX]P4L0M$($\7Y0Z(7:,7=65J7]B26N\L M,I]PK87RCUL0"KDA$<'N"JFO)%Z09C661,FR@_DF7)\!@:B(!XFP:Z' M-7?F4SS6===Z33S?!=>J`EK'7MR]_KWEO?U'M4I'S]7J]R/O+7Z>&MR;6?3= M]W_ZCO?VT^G=AZOKDSJS#?'_U)/?!Z/[^$>CAG\>]H,O#Z?XES$/[>'B/P_5 MJ^OSB^N'DVJC=C2%4;DPR'49SM#05D9LTSB#U3%;!!3X]+W/F4TYSTG/0MQD M,GUK]_ET=1"WXAZ=<15Z\57=%@B^Z;W\P MG@@W&&RW.W5<#'CA@X&31-<&+O::/A*3&(YM7-*^ZQ-W9G0K!MY$JQD/,%#! M-!BPRM#:\0S9$Z@>5PS`8](A\,TT^C-#^6=B&:HJ@H3?8P61N"8WWCOPC_$F MHOSR]/Z]3G;JK#/'9$,V$!NG3SZ]/]/G]AI'%<%CANR;)UG<$X&`0G#UV M8]-,,J5AM@-JBZ!\EPM-ZRNS4C-..7X.]:W9$PK7K,0( M&8-&V8X'^`?.R!8M2OBU*SLA*H(('$.,)\?](A:J>J1-V4PK1A#@0]14&SX" M]-_UZI7C7D=JN5JP5"UXJ!,B<,19R5#9I]0V15UMZL@5!UPS]5WRIWB/S!A" MTB8X-2$V*"'NFUR"8*O@W0RYS1`D&\Z,H2^,M;P_++37$9#0_R&7<:[3]TC` M;3H`UB(W32P9.*Y!93?J,,@4)+J1.&X7AF4J#M=$4=B)_($@5%M^8%F.W_*` MIFBT8!Y*)1EXCLL-ES#XQ/T^'I9XN'[3\?NXAR.P8(@T`[+&@5#VYOE>,R)% M6Z`.IB,$!\R^Y9M42`TQ__`E&SGB0"I0KO"(1V%&Y@PL$/#(Q((-;9DR^^AB`BVW(O_K(BFBIXES8$N_< M9J!%2*[M1=[EUK%`'RA_@.#FO875BBU$.LV-1SKW_F2"W(9-T9:M>]5@X=N+ MX+&E,+NWD%6`'@@)V65_09*``[((!\KMW7P-)8%G%YPBZEFDYQI=6840*6&L7*WR?901P`0'\!!F^:[F3DA0:[E0QA'E@"X<0Q:![$$*F9`.\`OA6$`7- MF:/MGI`O("3!&J78<.Y/IM*S"I=`AD,Z\)0#0G^.OD5Y%:!$"[!T;Q($7);# M508G_<0(,6?-D5A,E>=X6>J&\[+(<8,>5AQ$@R8I4UQ-TB8)K1/%J'C.!&X? MXBX7U`^2+,L77,GFCRN/)`+_;*J["2)]FX!S),_*"TM8N'>@VLX3&@$>1XQO M*>$BM,I&!],'ZF04PQ>(C,>,0Q3#4$]QK2ZC:%YPWB.!Q?DP!PASPVA';"A# M!P^A]",5D44?>8(7[]5ANPGC16S(7(A"Y?M0>$7Q#AM4!9]E3(ZR)IZ(2!T_ MHD@A<__PS9':K;[CRXT=J/J:8`==)CTX`VP@&!Q+B@_W$KLJQ=.E*N@F)D.S M.46+:ZOX52Z?0T0?XDX!82@B$*4+S@"@J*`_@*CQ(!H<=\9[0>X@9,6GPYNBO!"&NMC=: M;"QR(]AAJ<34+)W9'A1KMK&F*V-=_(-&U=U=V^]`IL`*4#3)-`B$+0;X>U6-$$!NIAR"M6Y9&*R=1');>!1BN@D0L:4T+' MT_LSHWE&D6K6PNR9[9"+=#CE`'@FSHB03SXPE M#>IJJ?'&!ET!0^>X/P26^TEU0L)DT0IIP)`^T`[TB*F@-]H5H3Y@4O!3>-E!(9SCJXA39"@$=F<*_G9,<&[H'^DS M=0=,1M42IQ.$-:[Q!)$!$?9)9SE]%N40GL5KA9H)86-NL#E8]X8!X8R:<1E; M5RC^U*PH5_Q$1101VZ_Y/154:]8T<,FP+8Y+\^F/=--!3L?Q'61#-@('7CK/ M3(NUQ]'YPE7DYG9Z2N.[Z"N%,J.![#9U@WI)0*#D6?,GH9M:[G$>YC7RP`NE4`X,EL2']6_(Q6#%^BJF(E!'@\V@^O+9+:8C_&;P!546XFLI68RX:1L1B&4ZX^"98TBCK/6 M5V5%#.9^\HC("1)+#).UO!(=G,QF MV:EP2V>[$]O4+-,V-5?;)J5),J$'[;$3&Q<6`S2[%\0SL@BC(8%`RP?HA">` MX`0.MM0B;@9I<_+Q-@7$$G%!((%TB7@>K)L_Q&,^+`X\.I:/R1R`L8?H$$3% M`,(CCH@Q8'HC,[\8&3^\Q1D3QZ16%:)C>&)&52>!43)4MVF!"XDS#<#`4[1+ M`1Q5GA;5#XSG*F*,`P:]KUH4^K.*#D+2A(4\4G;5:)5)-5JKJ4::KU?^*BH\ MRJS`L9S1+-*5%`^GN;6P"!LY/?7-;JQ@SFPZ?H@Q'T%P680!OZ\+-I88"1]7 M@G,9"-KEK2!Y"AV4F,V@Q4!6?J?R\HA>5TF-*^?9Z/BN+,^(DWF97:$F!=%5 ME&<'KC;,M=4>!XT1P6H`Z"J^K&;\1H."<-1<$1XC:[5:RPH(5U7E5.:""+O. MLRA:JKPL*EH'#,`:YX"H4%4.LF6K%_(:XNHI#0A7]2]3U$"!?$BC@Y/\LIF6 M8<&U3!!GET+,SI$36+G:I8*)&E(L18K3)SL4].1,`:RL0`4]1HF!)C.%O(CV`'F^I`Y_`"$8ZK""FG;FZ=LB MZ!.&]PG+:.IP%6M8P4UBC(H<#8#$S[E%_Z/IB,86="F= M=ET+=4+?HMD)=!AS_(LZ>&5$1.1"A&/`MAF@IV8D(S'`%7#+A!#=&`T[AF3;#.K?C/H%_DXN=IK(Y=;Y0(:FKH&))?C.>9@W"X$E? M"\3P$HPHQ8LN!"]K2_"1.!GV80^#PF&>Y2%5ZKP9^X)TO=5>CIJK;2_QYK'H M;N>#ENI&E=:MMONU-M[NIQ9LB!4;^I)S8MZPH3A/'E9Q[`$#@N>"*N%]M,8P M>1,AIF=Z0H:]?"(#D=)8W@4]Z^J2_M2^W(BYYR?(UV,`=J6][X^HKKS#+@_9R M:>S_$UL(3%QZYI(?$%TJ:GNB!(%B"2,ZS;H(8I\'X"=&LGS:Z#8JQ[UN>*`] MS%)L_9`TW2WD%9'T^W0[DJ6CC[CYOU5B/9JZR%JRJ\4MUSVE40Y0#T M#A,LK,(AJYM[(B!($&X$S82XTO3&:FCK.`"C+^;]S=WYQ5WU_J9 M$,*KKS]>7#Y$7]Z>GI]?77\(!MO;+A[N;S]?GU;.;CS=W)^)P1'9] M1C,$'#'^MZOSAY]/6K6.R/J"YW=7'WY6`Q3FAYO;.6KDJ#ER<"A,C6OSH6=F M,:+9+@T?@NQW)WQHU+NE842W,?5VQ89&>?2BVY2^:N.,D']JMF(ML]&W"`0` ML(4&A\S2_(K-!YZ(1$:Z[WB>,TD8Z?6R5JP;__JC_[CD>9)?`G.Q-]L*XT,7VG9QAH1@;`7[3;>-AP`][TUZ*W3C& M`^3TS=A(P0WY]XV5W-;Q!?@V'M]S(/_#LZ,-U-RVR._7[0ZVS^]OS#&TVO_: M1'%JFQORK7F'K"W9YP;[&L[>`[SZA&!?PRDYE_=V>E-V^BQH#,/.X8%XAQ_V M?\D7[,[VMKM4=F5ONS<5(#:[E4ZOL[?PI=B+2KU=W[N!K;J!7^??R[JW_7O; M_RIL_QMI_/>%_)+L!IK_;13RRV7_LUK0]F6;HLU_<9S>NX%OFM=?G9G_6KB] M/Y#=O"6_BF[S3?$7:'GL-V/VQ[*ELC3[8]G-!Y;JCO91O5@/L#^=W?3.:-Y" M_HDW=<-/)GLL2$EW<[] M;S5+PXC.>PG]N^,;E).[KS\'^YD=XVNS=HK'?-[1R>8.O<+DE:N[]W MOA31"^Z=E^\%!YMSNKM6ZCP>?=O`VZ.]==S+Y%-OD)V[QG+8UCVGG$C5S/KE6[K M!9WW>_^Y]Y]?J:@78WP.*],]VGF5\WA_=NLKQIYK=[.KVK2WZO M^8RZ?*[QFSR@WDX0_D8FG"^X[?=ZSW%+Z%*_U4/<+0E_,9C7S>%]#EKZ''2+%\.^#E^(AYZ95YLVD(]N<0->L:/<`;/+X#)W=S6U MC#>&7[&;W3ZSR^)PRW,'./J)[44_EAW_N7:_S^F?/C#ZXA'OW6[U)[6/-_Z3 MVM'R#+F^G`BW\Q/MGX@[&!O>V'7\T1@^S7+\-/O14V008#QS6Q!@^VQAL;I_=G1O?HJ-JH)WXW&V][$VOV%T9+>#'\?^U=6V^B M0!1^[K_PK2]KN;2*&FK2U#8QN]N:W>W#/C74F=9)!%S`M?OO]\Q%\,)-=!`2 M&I,JS)SSG?L,PP"_7\QU_)8?69>][WM_"_A:MY0BHN_TAB\^*(TXP)A8V=YRR1CC`GDT<^ES8&6U`MX\[;LN&;AXC$&'`S,/H M^\(1CSKVGO-DCAL6B"(W,2"WPY99^GD9`#6';A]O+1W"8Y6?NMR*WS'$KZ[V M7J?6@@36G+:%%@A/B6W-?3C_]'@Y5#=`[)(_"7/F?,SW2N=-]]A3G['F"XM` M-Z&(TG%XF+[['2-L>0YT*M\(O*@>SO:=S`=CB`T:K\_OC^[20=CS>=MTSB/& MN?]*_^D9+MA1V9^II+$[,9X4K^R4C"6OE[;+!I;';0Q5T4L7_Y.2KL+@)`#/W3\#X@B4G%D>D-[6[HG])`)#A!#M;'9-#< M"4Q>$L^5LZ2R/S!-2<62UQ>E@DCWQ9RLJ37';/3)9P?<8WFG)[QBIW+DR6B: MENZI6D_K]GL;Z'+QEPXYQ;.UGEXUN'DC0=,[UY73]4%CT4H@3H@S33?T8ECW MRL1O4$9&#'LWW;XA$4%2ULWD6SC;YTBKG;V\ M>MJ"D^UXG>T\*8-]7O\SMK.>#"C9;MA7F3M(19'DBH;1-S)Y"X(M@O8OM,+Y M"Q-(D^`?^WYA$D1_OA/LM?SI#-OX]G(6!(N!HJQ6JRL?3Z\^W+_*_?@KA+^J M:AU=56\`0M2-TU0VB)J+<'`,/P";%XRL``_IHR?:ZG5;U4PE.LI;80>MV^AM M56_K?4H2A2U,)2)J*D+$/7&I_KIJ]RQR$H=:(1`2=.$#O<6QPR0XEZ6V)>`V M*"(!&\2>6P*-2=`K(L%(7-LZHR"[00/VZ*<&32CNX4$3BEN=')$I[E$Y@HIK M5,(_5:-PA.U>?9;-$1G@S\6<3$GP'=MO0!L1.$N?AGY[ M&0V9Q9K$PY\EX+D/'\-[]TD`ZKK9/1?@A0K`B9E*+(\A.(,`<:B&"V6`N"6& M6BJ8X6<3F$KJ-VG@5T==WX6R3$"6L2.YQ^F\I['KTWQ;0L33?U\91:3;O+IHXJ M+F%2*W,-,>6>C%I:0_JDMD1C-*6U!D9JZG`ES=(4[?)-$'N+5QTM('=2>]3= M)DV9+D._3>4]C]Z;8EJ6IIOZ>*Q6:7EC*J5W6O.V-K;HLP*&Q'=O=,T8P!E3 M61]D!&BG[=[BQMAM`GPK>F;?%Q]-L,E33=\N\(JV1@O M!*>=CHS8"#NN39PXYE*A#*4BAL2OOP'4$L#!!0````(`+MHS$"@ MQX6Z8@0``'HJ```5`!P`<&EN:2TR,#$R,#(R.5]C86PN>&UL550)``/Q=M=/ M\7;73W5X"P`!!"4.```$.0$``-U:W6_:.A1_[J3]#[GL(4\A!#IIH'(G1M8T;[M-5NV!=1G`:;SOHT%<]Z]>]MU//O]WZ]?7?WE.-8G8$.">"0LQ\(W MF(`UB;"$U(;5:5Y>=BXMRW&T!L'T>T__F2(!EO)%1;^QD'+9<]WU>MW<3#EI M,CYWVZU6QTT%&Z]?75S$PKV-P'L*ZTXJ[KG?_AU/_`6$R,%42$3]1%'@GHBO MCYF/I`;VM$NK4$)_+W8DR`)"B8<4H>G*[A'Y#X'!) M(+VVX##K-Y:88B>UHLEX4HQODLOW M`R&4\]0R05,@??O@IEM/:$,D%@,:Z(^/_T=XA0A0*09RB#C?JLQ^122"@LA/ MT\T"RW`^X/L8$?=3-^K?F'"[L.03"5=$81A;<]2*%Z;Z,\["H_RFSEC5^*U( MJ%#84KM!Q+88#X`G*_,:\'PA=U]J(G",T103+#$4%5A6HJ8@![[/(I7;6[1% M4P+#B'.5ZJ*&R!>NNXYR$ITMIB*(9E?/=03_L3M0J83@%G$-KIR<$@7#"2J# MFD]2VQ"2,L#4+*LKA'BD=E0\#^ MDN4CF>\-AWFF)M1@:VC$DUOOA31;GE25I?+*S9OTSWU,F4A53:$>W3[//B^! MQXZ>?5XIL/;[#RX%@=2S!=UR-L-RS$31D)D1J&F7O(,5T*AP"GZX77').*I/./FR5049CV8SFS\Y^#ZX05SWD6$\<+T`R3^Z'J\HCH$&[@ M**TY`G7GL[`2=%KS`)E=V/\`57B(VB,'0:@($E*C6T&"KJ#,G](RFJ23H9M] M3-*-#4+$P>6T3J'8'\'-,;A\,CI&'GY^W1IAR+'GM_=7<@+2N`U'_1.5NR.W MAF.$?B1\0]CZ+*>(1V/U'B(>XZAG??X$4H>@ZF&%%;H/VR\"@A%]***!KYJA M[$%V!0,U;4$JPA%53$#)26E?IN[-ISHIV=X^P&OV9*-2B9>&MW5'\KF3IGF;"DWF"+J_\26DF>@OE.- M#Q"(&U4"&8ZVUS`M*N92%4.+MX2R@V&R)!MF[S_9V$="1/JU%#65L3!D-'[2 M?@*=^7HOA]."O)B]_^2_1W(+'+/@<+6M]"I-@8FZZ7X.WH.I\>3]ZQDM_8)2 MDMM!9_D%+KFA_^A7&=65'U!+`P04````"`"[:,Q`E2B?C1()``"=@```%0`< M`'!I;FDM,C`Q,C`R,CE?9&5F+GAM;%54"0`#\7;73_%VUT]U>`L``00E#@`` M!#D!``#M75M3X[@2?IZMVO^0G7W(DPF!X=1"+;N5X7***A8H8,[9?9I2[$ZB M6D7.2G((Y]"'@M%I?]R>UI)8L?OU]-2>])3".?7K:'^[M M]WM`7=_#='K:Q]QW?OGEZ-@9]G__[<UH)]9>3B#GJD3,\<`Z'>RONI8!.,,E4LY@A-D>8+H$+Z4P* M3WS/]>=2Y_!@_^#@.%54*5_3*X4BL5^&Q\?'@_#;M+14YXD7\;3VHT'T94X: M5\!Y\;7D]U-$,&(N\PG? M.9XO""3/9@PF6AP)<$7(D:+B9Z5ML#6FF03"W&`,CGP*5#7I!C&6:=\>\XLN MQX,)"HAH$'%1=Z-X?=5%W@9NI+H!M*$B9P[S,;`FH6;TIG`F(/,(3:+*((2, M/?;]W'<#Z0N1?(ZH=T$%%L]7=.)+'<*H92\PQ4ZB/(1MK#MED6PZ4H]Z>BW_ MS%0**P'4`R^I5N%_2XM#4(,25$W[_RLB*DH^S``$W]31627O[M%L]:KVN'KB MN^DZ^T0-M#[KITWJISO6!/%QV!4"[DP16JC*A@,@@B=/E/%#9W\8CZP_QX^_ M/P@D0-'YB,8$DAH(&@,Y[6N$!BU#E9S`E?R5U\%]%6P)\HAS2>UHS`5#KM#` MS0FEH;ZVPQ'+@I;A,U$71](LYMI0FY2>,']>Z;JD6E^+N!=P6;N_4#@1Z?=\ MY@&+9KLM^?T,\9F,3^KCXI\`+Q&1)O&1.$.,/M.?;:XS&F$AG05U$*I/L0%@J-=!F&LX"QM1, MRIB-?(%62:EH3QI6"O;:%W]LTJR4&FK= M\''FS^<^K>6B(-8A(HHF6A>P1IZ'(S1W"'M7]`PML%#0RF=7&ND.<:(UV+IX M=0Y+(/Y"!6$9C:=P006P!<,_37E) M%^DB.1F3/Q9F[[(P>\',;R>W"V#AT^^'-/@^%B)[=Y*[!Z60`/M M-O++UQT(B*^F6+=>BCL1G5ZL%D!Y[:DPO7P'>*@PML$%4C&"3C"1@R+E`5&5 M7T*A49<(M.K.VE:AO%IFE77M^]]`I2ED1+V1-Y=.5&8(O(38,$TKKRME/SG& M]EN7&;AC_@0X#_&4=!6M6'WUD51K,JJCWJBZ)_]1(4N556:LY ME5<8'RF5W4NIW(!0!,M1>(EEV_GZ_(V#=T5?)D(C5RX-3-X-VT"1Q0%W&_=8 MM^"51EQ1V=&A8M*8E6F5FQUW697DTX"\Q1=1M8`Y+#&@L+[=C7&J<8UV7-+=\ MZW"["Q2OXR[KAMCR>Z?N@&'?R\\4=4<@UU'1@6%U/9=TA-&=N4IM&PX-KU-K M\]7=8+&(-E`02?+[J>LZZ^X+,2S=`0*-'6'=(?(K]0HY<*%N$-"F&E(B[9*Q M7GO+YA'2=EHW*XURS(]H!5PAE(.T/N^3%^PN)46;S6:7'YO-#6XVIU]QCZ^1 M:&+;N4QMJQO098`^MJ)-H4:7'\B5X,*GX>1DA6MWI4O+O%T_+KF>OZ9?9_Q? MVJ?+S=8/'W4]OJT#:%DSSL.XKCMV5BK[AH-,[M+_&LZJ&F+FZ%FYR=:-_%M3 M\WWX/N1$_T#B+=F1EG2O:\5[6-^DS_D?F8E28;5:$&QUYE;9\+*KTZ*%UG6C M5(ZRFH6"7$=(*-IG7296.GF[@_&5#AO-,\K?#WG=Y;ST M`ZIR`Q&*G%\K12UV;;6);_YJ\@V$KV1=^NQQ!M&>5(ECRZ0L]VFI8=8-].%T M,;J_)KH.-D(:T7\#3^%7^J!G5-ABHM9UPYN_C)9I-7\!R@_UY3(6>UACU,C_&G!I/M_XC;*-ZGKW?/]&*%O@ MZR&8SQ%[OIT\X"G%$^PB*N)CZRH\^02[&!K@RK">%GDR1-@"1^FSC(\,48[< MK2ZZ,M#<(@]:3"UX/LYUAQU="+G#^8ME64E3Q+ZD MA>-'*]2UC4AI[U`<`FJ7LHBL=M5]^-'#_>]'E??&Q(G>7`>Y#'%LB9X;# M'\GA<#A\^\/3V@,/*(QPX+\[F!P='P#D.X&+_?MW!S@*1F_>O#X930Y^^/Z; MK]_^930"-R@X]V"81&`$\!7V$)@E.$8Y#?#JZ-MO7WT+P&A$:WC8_WQ*?RQ@ MA`#AY4?O7JSB>',Z'C\^/AX]+4+O*`COQR^/CU^-\X(OOOGZJZ]8X=.G")N:LT!J.L!_%T'>RBA$^C=CGUX$#8]HP.4O`+4'_&N7%1O2C MT>3EZ-7DZ"ER"X(NL5=BLUG!<`VQ_X"BF"C31X_1D1.L"2\,!S3^F,?W<,8N52Y)U2YD^^HY9Z%L,PUI"[4+\WR>=D MMD%[R5RHV9^T00R]_:3=U4RE32=4^L$U^:TD-'J*D>\B-Q>;TA&,8\:&S124 M<$XY<(HT#SPZ@P;A05$3!QOLXU$^C[%VDLGOTS2*$CHOW"ZO@H3($48S,@6B M**_+A'YW("PZ+HI"RY>$(26")'10A2+Y[Y.*`$P?!Q)]4)('=*$BU.D2B/S1 MQ]G!]SEM$"S!,J,.(D;^[7@GS-#BNX&3K)$?LU6O73.`FX1DG0+Q"H$-&]>B MAIV%#@A"4CVS&8KMA*&3?T!^E8B=E1@[`1%K$X_R#F#5EV&PEB`FYQPH*'+< M%NC%!7,)HP43.XE&]Q!NZ$(^&2,OCO)/Z)"8C(XGF6WPU^SC3^2C2Q^._8VZ6S*)06IY7SYMD!_5UB%^.>WQPV6M,TB8 M)0"VI$%.V^1PT1)<.";VD7Z(T<'50'4(2&"C84:1W?<:S>$3BLX641Q")VZR MH!I*Z1E/?+9:=A,C"QA=6_I:TMR2*2%3O:J,=+H_ MIV5+U_/:6!W=S=ILV]D1QBW#:S^27:O>2CSY=^C&.G^^2A8>=*R^` MU0'?7&;OCA:RU.GME"A(J0)&UI:.%[8Y[WT%/7<+@?,D#(DE]0%M@I"N+3.R MD4NJ(UY:W``PQ((8P$C&`&PY@)2%?7@1JZ(.'95.Z1A%P7H=^+,X<#ZG&]_; M)*8N6^K3YV-)5,D$HA2$,H$KQ@8P/H<@Y00*K"S$EX)B&E"FW%W[6Z(W*+X. MHN@J".8QU0%:D"9;(/H3Q&EW%CUC=/9YAJ-N42E7TSR@ZMB?+ MAF1V1!;89TBVT4?-C6_4B#0#M+,H0C%O\LF^U`9/F8F^5SZE9](3WUY"!?>[ M7,PAD%MN:A6C35W>[?;Y`[K'="GVXQNXKO81MYB!+7(S8P.;XAUA0"G;`@!9 MR^N[7I'.^YNBMH<"%SARR$XL"=$AH&A]P+ M%M67!>HR(_\&/;*O>$:V8F7M$=A.2`-[N8@R!)AQ9,Y3Q\+PK'9:J6)SG[[K M$9;)9N,AYO#VJ%?LR@L>IS[IB35S@$M5"8Z#&*LG-=OH&O3L*$P=]:8*U]9!;C!C80NV#Q M#,)LP=^DK&R#ZS[Z:;"Q]^S1_H#;&J9=@K);"!+J]-32>IN`(HT]H>Q`SH^N MGFV/P.UHHO"`P4@[[3[JUS_B-S6C_X;P_8K,`V+C.,J=(+3IA3-M$*]@#$A)D!`(TPML#O2_P$MO M,G^.(ISZ&P_7&"ZPE\;1^2[S@JX"CU[]IO=3XV?.L)!6TQX=JH+IQZ`4.+%) MNLCK[W`31/\`%VB)'2R\DS-D^Q0B6,PTPI>GAP?'A^S?\#)3I%24^H1QRL`J1\*/%`Q MJ)7UM^.CX^,)C<=/2X%IHYEU"EX?3MY,#K\[><.^>MW,XA"0'QM$=P_(>[8- MS[QN$,08-@!@D!5"OA@8G?<[F>([FL.[FZYMPV]#HP53[V#1L(X3)#2U!GRF M]W;$SGU.8?UH6:$0.K#.*9-IE)&V#23BEM="517T/\B$ETDBV2,**IB<#CG" M:"W?V67B+V.ZX2A`,/L(NZ//J"(8LT/\:^RC*?F5'T%4*V@@6HC'7"O^(J<* M?J=T`2/\;]O`PV][/?Y'K/EN(^=_#3PR_\'PF::%#?EY"ZKE#,3.J/?]CR,N,IV@BF%9N0\6&[N0PV M!5:V(*:M2HI^\?:=->#=Q'3;+?=(E$J;OY%8%L/X9<3T#,<6<"EJ07H%L:DW MNEJUS@BB78KJ*P\V948I?Z^U2C6RTMHZY00!I6@+"KA-+2Y&`K7V>MW=03EU8Q2C\>`*90UXQH-,Z)[>**D1`$W=.O[D],$N9PT=47L!( M/H\R,]T`.DK+I,-[/PFE\6\R,8?*,U)N:E.&D::N[S&*'3T@+]A0BV`6PWM$ M-A@HW(28QMZSL]PSAVP^$C:4TEM-U1H<5!L@K!\5;ZQQFH[VG`EP4[[%?/_N MCB6(*$_;8&Q.B[7X>\,8&<`=.Z>G#3)7;%K(G!NVQ-20"Y;1M-?[6FHRU_/: MH.BN]J_9N<`5CASHT31XE[Y[0<1HV,IRBVKM:F4"F#C428D#2AUN%CK/#$@%"Z$U]%SW]C*J1XO.!['Y,5$/IQ=K!-KY,''ED3421+Y:%867\Y:B6DWDWM]9H> M`@5+4&`*=EQ!SM9TA++Y-@K#E=4;:LL8VT]1M05\#\CVF3IA$:$_$C(U7#Z0 M'[)X?VYQ`\D1Q(+HC;&<-DB)6X/K>0]4NJ'W<+("L"4X$E0P%58F$*:? M^=HVD,GUP@D\D_925X9E?CB&;$,*M^F"T*8FM>\?;WG^T]G-CY>SZ7 M'V87EU?3\^E<$&^I5$TKWK*-8%I`2?F`Z0TH<@(9*UL0TU8EQ7C+]IVE@2W3XTO/O14$`/(XW,]*:-G*+TI8]^!%5)T>&L8'B/BF>PX?8EO/0])Q`' MCS!T(^"D@C!J63UKED^^HDI@%N"GYZ2XI;O3-T&,U--3J],O2Z;^K^;]CZ-94R]\)OF:UNF'C#H[BFS%D# MDHO=I\WB6R+Z_Y\IKFUZ!1KE/E3<-'QZ7$+@!L?0^TCS?XK=Q?6"^@L$E[FI M]SU[@]G9!OR=4YVZ3HWVV(F,G;ZV*M1M`VB`GW7+WU*^KOO![]E<:CE M0H8>`#=I`9S-9I?SF6V0:&YG\QO;@Z_5E6!IZ7D[&S]Q, M2"^Y(_*%!>K+S]74P-3G<\HQQ#YR+V'HDQ5(O&7G%#;P2+)(",,7TFW#D+CQ M]5>!Y5W0XZ+JNIBZXZ!W!S'9FF7.!2&(Q'7TEUP5D;0@M67`GJD=K&`_3 M$ZRQI@@G67Y[;!LI2OJH&1WJ<+/1]:7M\NK3U67JA(6]\$:Y@*D/VOJ\[&B> MVBMV^[;1;K^>OC_/GA>:*\G6.<-17J^#MY@YHFF:2Z5$^:97-*.-$*]JEJ?\ M5]:$_+UH(=1ZC,C++-(\@$#\.J1J+?V8/36Q=)OS*_'N,2=M''P>)[E-3 M3"W^'Y%/5A&/"'+FKK&/J8^)OFB4O1S'09^LEC;Z%,7205_&@D$- MEIC8ACA%9501UZJ3ACKU:!DNIUC9\-E(ET%SE>,2B^/FVNE$?*1A+GI./R$" M3?2EE@YA5])@,H0:>Y.I$%A:-LL3(=04P$^#P.F`/CU+G:$.0')ZS&=E"R9$C:W;\3SU]NJ&FK+P2$'*YG(9$\ZD.LL.(G)M@T1C MNQL<)#Q=#^[3;^?-[\R/WZT'WS;42)2@Z.ON,]/.;\CS?O:#1W^&8!3XR&61 M+M6S('EY`]EW)*(8R,-#.8P^4Q8@YY%&]H2V`$E9&_7L/$H]T[5E.R=D!>8L M^]J(#5MD9,1PI01M0D%30YL,U+I*>]Q2LPL8PM/C4A'][7$#0^V@65MZ7=3( MVJZ6J]8^0U$>D)](H_UKQ0R$GS0SUD%"3M/T"8J.K,(#DYRP;>CE-;@>&"." MQ8"O!.[BACF`%M4P_UI@71QS5V6S"&BX96$;F!2T(7TYD-<[`[S(D8;]$PDW MQ#ZCU\>?L/2MY,8ZYM[K$(FD%C*#6K_U!M_"\O02C326UP2A@KX.ZZ^G9^^GU=#Z]M.XJB*#%5?1(-=ZU M=R&]*<]_S:BYG!%_0R-K(XZ'+&NXC6\8"1O?Y(P0*+Y'[:WH\$ZM6 M3M^LXK'60,UK=(/U)U3Y4+%8BGX7 M227#L5==>%]J,5?6.V#4="*.N;+'#4.$F8?0CXCA2G,@ID[T%8JQ`[U=KE3I M(UJMZ9A)&;*/Z%IH+?*PSL^\MTH:\W+LWYU#)JU1`6ISA0Z2V!A]I:N0W3[/ M_V)7$G]U/,[W M`0?`P84??WE>!*U'2!DB^.*H>WQRU(+8(S["LXLCQ$C[_?MWY^WNT2___N'[ MC_]JMUO7D/0#0"/6:K?0$`6P-8Y0"-,R6F?';]^>O6VUVFVA$2#\UP?Q8P(8 M;/%W87;Q9AZ&RP^=SM/3T_'SA`;'A,XZIR[?SG]ZNQ-X<+T$:8A0![*T6&/K#X^17Q0"@P6E+_/YR M-]H(AXY0ZB"?/@R(%RT@#M/?/>Q?XA"%+R,\);P,P>2;5NS,+18 M!C!]-J=P>O%FB3!JIX4+CGXT+KNS]FA)(>-B\?,K_B#W6O@<0NQ#/WVQ\.`U M?19FK>P*B).5\T+VB-V$A!5Z8EA.`"0PNCHS5.IN: MF*V*#'K',_+8\2$2"'7%/X3YW?9)=]7.?N2/'I+7W\$9$F_%X358P(+!2K&L M@5EN>S1O+*!>6B3_9TSLD;(EK"0Z2T!Y>6UOC@(_U9Y2LM@`P-0(HO&A%3%N M#5D*11`_V14$_HL+1(6(>"/X+`57''*6H8T2H799S\=.> MFP-9+`@>A\3[:\S'DI#=1*$8=8MIF;IMZ)01$ MZ;R"F[W/H=<#CR%_(FLA*DG'^%`ZK&!B[[/LQ+!D^FG&15;6:39R3BOXV-N4 M._'A-IH$R!L&!!1SD7(9Q_"7.*G`_>O\^V.GY-P5?U!W\OT3"$12?SR',&3; M9MGSA5A(I^<-V*7:3@&;Q#4B8NT9`,ND[L(@9.F38B5>/7X0(S$8)Q/!)"C. MH15".[6P&DSEG,`1_VF<>Z4,^O8,]!CC-56Q_*(0:@KR MI4J31;_H6..0[P,VYZ%;_+K\.T*/(.`NL5[8!Y2^\"CS!P@B5>LUT[7,D[QJ M93DRA$!-78N[-85$NI?)0`IS8YM#OGT",:2=IN;MIDUG[;4"?4RU::\D!`$ M5GFY0F""`A0B6!4+99).!$2IBZ^TTE@+$:L,DSD?107+M&CJE(*7DL>-Z[1Z MGD+!,(`=U)@@7O:;DX![P,3P-'RIZ(HT"DZ,$'0.O])^ MF.W9N4UK4VRU;K(DD[3.1U75RO(B=;5Q'5!FK5P[=2V*.45%V) M-;<`^2/*3A%GLR1]5[$)T; M.68'SM@W9K52S2F.JT%0[W3U$X)Q3]`WTC MYDI*#C)6=KQQ685,XF/#AF:BZ01G1A`T+N-0.L)2V;YT&JX19=JR+$[Z2];& M6\6-R5E)NTE,ZNHKG3^LD13U^3MPE_]83=3&^6D,8OVGJZ MK2C-PDQ;88F=VG\''R&.*N?0)3';,S%WIL@JA+_-@+_-@+=HJ!4-M#%H:[N? MM3.-PWD5D?'L\GD),:N,C&IY)YC0N%O?_IX=]F++[Y?J\PXS"H390UAJ$A(! MRU14UBG!B,ROQK6.7R'FK@0][/?\!:=&N!&B1[AR3-%&JK1$68KA&M!)SH M_K,.J5N,"F:PE%_2D[%-"8TF9BM(*K*D%C)PXN3F,"!/M23@UH59SK^M#7$S MG_4M!?1_E`*ZAJ&HK[S/?D2\*7QZ^<*@/$?AUP]CT]$3`ZV;E%04QC4]GW; M`-1$ED>81RZH&6;F92QSLWVU+'"7=;MQM'#C*`1BSWGR.^/@Z@Q"1:/;H("# M('03P!J7,RD;7S@=;$QR4<\RMYM78SVG)5@.Z`:/LK<;G[S>J(@#JQI.G=8V MCWD[CZEL\UQ;?VT,V`%EEA1N#Q$&V*MA#*XKR.4QN!:@QD4#;KT'H<^&'(!, M!'L9P(F*3ZU*,UN\0:4MY(HUH#1NP)XU5VP^%*>;;J:9C6\&1,KU#HY-!3R- M:Y;FGN\<=`^#Y$T`.Z!.6G[98'(%<7&[! M,V3"0C["5*<^BX(NDU+VNF)Z9&&/1O;FE=7=2'7LUI`5:WG?ALRDFK:6_]:[ M_O5R/+H>W]_T/_]VC_NA>\^EB(S7;.S>:?VAJ4P;W* MSP?*OC:/D'5"4L]'2-BX!J[A]4\N,7LA5Y2"(L9N:)%Y+9LE*TT>3HG:SQP*DMCJ7A4G]R`E=Q0GOB85)UK^!3_2=V'&"DWFN1- M@:AQ_<&@,8E/15UIK6-_G M?`U"_C-[?YE862:8%[#J'C]%C&/$MCXNNM6[+*Q*;&6GI1LHZ`Q@]$]LF[AI MA@3(3UH/]F\SJ:Y!J*=O6OL(2=,,Q]0^V:A-`\+)CK6QXY;/,! M0244AQ,%,OM-=P\"V<*LQH"L(36M.:U+U/3^,BG;VZ?-V[)6Q6*?KL%>NG7Z MP)OL.)HP^'=O&P`,CMO'V8?OFYY\ZO[@N&8+L<:IB35S"^HP#&)X@T-06,J[SQL\(Z;ON\V M?;?E.YEYQ/B3^?W]?6,QHVI.F;@#;=`]`?>Z$]I#4WW;!,QB^C;GFV>4(U/#%C*ZNP M9T(;*H(5^]"LBI,9GWII8VX::W=*Z>+)-J)ZDMAF#44A<0:\ZE`AI*$&YX:] MQ?O%@HE()C>O.M;S\]S]&XA($O:Y>5Q`]TBS^8+#4?9LIB#J'B&8N?F0?UHH M:*!?N8F2'&%;P[;-'D(TSH#$H^MEQSD%5<$&RX8L2"(7H`P#_33V1][SA!1" MM&]("$&*'S4@3B?[!H00X#]B+`'E^\:"D"#F+SS=+,Y3+ M\=(2;1&E4H;C:AD.XUX^[I=,!USJ6,&0&OP=12-,R<0G?2'"GA1($-N!'$7O M8LT$Z((\7X6N4O&U57')BCM.?U!Z'*AGU)#CZ(>U;,^ ME_<%)T/3F?2S%&9+F`*^U5 M,K4W9$JA),4>E-BBA`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````"`"[:,Q`MI*VSX@=``#G*0$`$0`8```````!```` MI($`````<&EN:2TR,#$R,#(R.2YX;6Q55`4``_%VUT]U>`L``00E#@``!#D! M``!02P$"'@,4````"`"[:,Q`H,>%NF($``!Z*@``%0`8```````!````I('3 M'0``<&EN:2TR,#$R,#(R.5]C86PN>&UL550%``/Q=M=/=7@+``$$)0X```0Y M`0``4$L!`AX#%`````@`NVC,0)4HGXT2"0``G8```!4`&````````0```*2! MA"(``'!I;FDM,C`Q,C`R,CE?9&5F+GAM;%54!0`#\7;73W5X"P`!!"4.```$ M.0$``%!+`0(>`Q0````(`+MHS$!3;>)*@Q(``(CH```5`!@```````$```"D M@>4K``!P:6YI+3(P,3(P,C(Y7VQA8BYX;6Q55`4``_%VUT]U>`L``00E#@`` M!#D!``!02P$"'@,4````"`"[:,Q`U)F\8)H+``":K```%0`8```````!```` MI(&W/@``<&EN:2TR,#$R,#(R.5]P&UL550%``/Q=M=/=7@+``$$)0X` M``0Y`0``4$L!`AX#%`````@`NVC,0'2GG5!O!0``X",``!$`&````````0`` M`*2!H$H``'!I;FDM,C`Q,C`R,CDN>'-D550%``/Q=M=/=7@+``$$)0X```0Y 9`0``4$L%!@`````&``8`&@(``%I0```````` ` end XML 15 R9.htm IDEA: XBRL DOCUMENT v2.4.0.6

Related Party Transactions
12 Months Ended

Feb. 29, 2012

Related Party Transactions

Related Party Transactions
3.

Related Party Transactions

During the periods ended February 29, 2012 and February 28, 2011, the Company’s President and CEO advanced $20,074 and $10,000, respectively, to the Company and paid expenses in the amount of $4,817 and $0, respectively, on behalf of the Company. Accordingly, these amounts have been recorded as due to related parties in the amounts of $34,891 and $10,000 at February 29, 2012 and February 28, 2011. The amounts owing are unsecured, non-interest bearing, and due on demand.

X

- Details

Name: fil_RelatedPartyTransactionAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for related party transactions, including the nature of the relationship(s), a description of the transactions, the amount of the transactions, the effects of any change in the method of establishing the terms of the transaction from the previous period, stated interest rate, expiration date, terms and manner of settlement per the agreement with the related party, and amounts due to or from related parties. If the entity and one or more other entities are under common ownership or management control and this control affects the operating results or financial position, disclosure includes the nature of the control relationship even if there are no transactions between the entities. Disclosure may also include the aggregate amount of current and deferred tax expense for each statement of earnings presented where the entity is a member of a group that files a consolidated tax return, the amount of any tax related balances due to or from affiliates as of the date of each statement of financial position presented, the principal provisions of the method by which the consolidated amount of current and deferred tax expense is allocated to the members of the group and the nature and effect of any changes in that method. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 3A

-Section 04

-Paragraph b

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 1-4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

+ Details

Name: us-gaap_RelatedPartyTransactionsDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 16 Financial_Report.xls IDEA: XBRL DOCUMENT begin 644 Financial_Report.xls M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O M;VL-"D-O;G1E;G0M5'EP93H@;75L=&EP87)T+W)E;&%T960[(&)O=6YD87)Y M/2(M+2TM/5].97AT4&%R=%]D9#0T.#@W-%]E,&$U7S1E,&-?83,R-5\Q8S5A M83!B,60R8F(B#0H-"E1H:7,@9&]C=6UE;G0@:7,@82!3:6YG;&4@1FEL92!7 M96(@4&%G92P@86QS;R!K;F]W;B!A'!L;W)E&UL;G,Z=CTS1")U&UL;G,Z;STS1")U&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX M.D5X8V5L5V]R:W-H965T5]);F9O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?3W!E#I.86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-T871E;65N='-?;V9?4W1O8VMH;VQD97)S7T1E9CPO>#I. M86UE/@T*("`@(#QX.E=O#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/E-U;6UA#I.86UE/@T*("`@(#QX.E=O#I%>&-E;%=O#I.86UE/@T*("`@(#QX.E=O M#I%>&-E;%=O#I.86UE/DEN8V]M95]487AE#I.86UE/@T*("`@ M(#QX.E=O#I%>&-E M;%=O#I.86UE/E-U8G-E<75E;G1?179E;G1S/"]X M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U#I%>&-E;%=O#I!8W1I=F53:&5E M=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0#I%>&-E;%=O7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^4$A!4DU! M($E.5D535$E.1R!.15=3+"!)3D,N/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$"!+97D\ M+W1D/@T*("`@("`@("`\=&0@8VQA2!#;VUM;VX@4W1O8VLL(%-H M87)E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S2!#=7)R96YT(%)E<&]R=&EN9R!3=&%T=7,\+W1D/@T*("`@ M("`@("`\=&0@8VQA2!& M:6QE'0^/'-P86X^ M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$ M'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\ M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$'0^,C`Q,SQS<&%N/CPO M'0^1ED\2!0=6)L:6,@1FQO870\+W1D/@T*("`@("`@ M("`\=&0@8VQA7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$F5D.B`Q,"PP,#`L,#`P('!R969E3PO=&0^#0H@("`@("`@(#QT9"!C;&%S'0O M:F%V87-C3X-"B`@("`\ M=&%B;&4@8VQAF5D/"]T9#X-"B`@("`@("`@ M/'1D(&-L87-S/3-$;G5M<#XQ,"PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^ M#0H@("`@("`@(#QT9"!C;&%SF5D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.3`L,#`P M+#`P,#QS<&%N/CPO7!E M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@ M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'!E;G-E'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@ M/'1R(&-L87-S/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B M;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM/5].97AT4&%R=%]D M9#0T.#@W-%]E,&$U7S1E,&-?83,R-5\Q8S5A83!B,60R8F(-"D-O;G1E;G0M M3&]C871I;VXZ(&9I;&4Z+R\O0SHO9&0T-#@X-S1?93!A-5\T93!C7V$S,C5? M,6,U86$P8C%D,F)B+U=O'0O:'1M;#L@8VAA6%B;&4\+W1D/@T*("`@("`@("`\=&0@8VQA M'!E;G-E'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S'0^/'-P M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S M/3-$'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@ M("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S65A'0^/'-P86X^/"]S<&%N/CPO M=&0^#0H@("`@("`@(#QT9"!C;&%S7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T* M#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O M;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA'0^/"$M+65G>"TM/CQP M('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&(^,2X\+V(^/"]P/B`\ M<"!S='EL93TS1"=415A4+4E.1$5.5#HM,2XU<'0[($U!4D=)3CHP:6X@,&EN M(#!P="<^/&(^3F%T=7)E(&]F($]P97)A=&EO;G,@86YD($-O;G1I;G5A;F-E M(&]F($)U6QE/3-$)TU!4D=)3CHP:6X@,&EN M(#!P="<^4&AA28C,30X.RD@=V%S(&EN8V]R<&]R871E9"!I;B!T:&4@4W1A=&4@ M;V8@3F5V861A(&]N($9E8G)U87)Y(#@L(#(P,3$N(%1H92!#;VUP86YY(&ES M(&$@1&5V96QO<&UE;G0@4W1A9V4@0V]M<&%N>2P@87,@9&5F:6YE9"!B>2!& M:6YA;F-I86P@06-C;W5N=&EN9R!3=&%N9&%R9',@0F]A6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P M="<^/&D^)FYB6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&D^/'4^/&9O;G0@6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^5&AE2`R.2P@,C`Q,BP@=&AE($-O M;7!A;GD@:&%S(&YO="!R96-O9VYI>F5D(&%N>2!R979E;G5E+"!A;F0@:&%S M(&$@=V]R:VEN9R!C87!I=&%L(&1E9FEC:70@86YD(&%N(&%C8W5M=6QA=&5D M(&1E9FEC:70@;V8@)#DP+#8Y-RX@5&AE(&-O;G1I;G5A=&EO;B!O9B!T:&4@ M0V]M<&%N>2!A28C,30V.W,@ M9G5T=7)E(&]P97)A=&EO;G,N(%1H97-E(&9A8W1O2!A;F0@8VQA'0O:F%V87-C M3X-"B`@("`\=&%B;&4@ M8VQA'0^ M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L M87-S/3-$6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^ M)FYB6QE/3-$)U1%6%0M24Y$ M14Y4.BTQ+C5P=#L@34%21TE..C!I;B`P:6X@,'!T)SY"87-I6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^ M)FYB2!H879E(&)E M96X@<')E<&%R960@:6X@86-C;W)D86YC92!W:71H(&%C8V]U;G1I;F<@<')I M;F-I<&QE2`R."X\+W`^(#QP('-T>6QE/3-$)TU! M4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)U1%6%0M24Y$14Y4.BTQ+C5P=#L@34%21TE..C!I;B`P:6X@ M,'!T)SY52!R96=U;&%R;'D@979A;'5A=&5S(&5S=&EM871E"!A'!E'!E;G-E2!A<'!A'!E2!T:&4@0V]M<&%N>2!M M87D@9&EF9F5R(&UA=&5R:6%L;'D@86YD(&%D=F5R2!F'1E;G0@=&AE6QE/3-$ M)TU!4D=)3CHP:6X@,&EN(#!P="<^5&AE($-O;7!A;GD@8V]N2!O M9B!T:')E92!M;VYT:',@;W(@;&5S6QE M/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)U1%6%0M24Y$14Y4.BTQ+C5P=#L@34%21TE..C!I M;B`P:6X@,'!T)SY"87-I8R!A;F0@1&EL=71E9"!.970@3&]S2!C;VUP=71E2!S=&]C:R!M971H;V0@86YD(&-O;G9E6QE/3-$)TU!4D=) M3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)U1%6%0M24Y$14Y4.BTQ+C5P=#L@34%21TE..C!I;B`P:6X@,'!T M)SY&:6YA;F-I86P@26YS=')U;65N=',\+W`^(#QP('-T>6QE/3-$)TU!4D=) M3CHP:6X@,&EN(#!P="<^)FYB2!I MF%T:6]N M('=I=&AI;B!T:&4@9F%I2!B92!U6QE M/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P M="<^)FYB6QE/3-$)U1%6%0M24Y$14Y4.C`N,C5I;CL@34%21TE..C!I;B`P:6X@ M,'!T)SX\:3Y,979E;"`R/"]I/CPO<#X@/'`@6QE/3-$)TU!4D=)3CHP:6X@ M,&EN(#!P="<^3&5V96P@,B!A<'!L:65S('1O(&%S2!S=6-H(&%S('%U;W1E9"!P2!F6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^5&AE($-O;7!A M;GDF(S$T-CMS(&9I;F%N8VEA;"!I;G-T6%B;&4L(&%N9"!A;6]U;G1S M(&1U92!T;R!R96QA=&5D('!A2!D871E6QE/3-$)U1%6%0M M24Y$14Y4.C`N,C5I;CL@34%21TE..C!I;B`P:6X@,'!T)SYF*3PO<#X@/'`@ M6QE/3-$)TU!4D=)3CHP M:6X@,&EN(#!P="<^05-#(#(R,"P@/&D^0V]M<')E:&5N6QE/3-$)U1%6%0M24Y$14Y4.C`N,C5I;CL@34%21TE..C!I;B`P:6X@,'!T M)SYG*3PO<#X@/'`@2!H87,@:6UP;&5M96YT960@86QL(&YE=R!A8V-O=6YT:6YG('!R;VYO M=6YC96UE;G1S('1H870@87)E(&EN(&5F9F5C="X@5&AE6QE/3-$)TU!4D=)3CHP M:6X@,&EN(#!P="<^)FYB6QE M/3-$)U1%6%0M24Y$14Y4.BTQ+C5P=#L@34%21TE..C!I;B`P:6X@,'!T)SY) M;F-O;64@5&%X97,\+W`^(#QP('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P M="<^)FYBF%T M:6]N(&ES(&UO2!H87,@ M861O<'1E9"!!4T,@-S0P("8C,30W.SQI/D%C8V]U;G1I;F<@9F]R($EN8V]M M92!487AE'0O:F%V87-C3X- M"B`@("`\=&%B;&4@8VQA2!42!42!46QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^1'5R:6YG('1H M92!P97)I;V1S(&5N9&5D($9E8G)U87)Y(#(Y+"`R,#$R(&%N9"!&96)R=6%R M>2`R."P@,C`Q,2P@=&AE($-O;7!A;GDF(S$T-CMS(%!R97-I9&5N="!A;F0@ M0T5/(&%D=F%N8V5D("0R,"PP-S0@86YD("0Q,"PP,#`L(')E2P@=&\@=&AE($-O;7!A;GD@86YD('!A:60@97AP96YS97,@:6X@=&AE(&%M M;W5N="!O9B`D-"PX,3<@86YD("0P+"!R97-P96-T:79E;'DL(&]N(&)E:&%L M9B!O9B!T:&4@0V]M<&%N>2X@06-C;W)D:6YG;'DL('1H97-E(&%M;W5N=',@ M:&%V92!B965N(')E8V]R9&5D(&%S(&1U92!T;R!R96QA=&5D('!A2`R.2P@,C`Q,B!A;F0@1F5B7!E.B!T97AT+VAT;6P[(&-H87)S M970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@ M:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M M;#L@8VAA'0^/"$M+65G>"TM/CQP M('-T>6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&(^-"X\+V(^/"]P/B`\ M<"!S='EL93TS1"=415A4+4E.1$5.5#HM,2XU<'0[($U!4D=)3CHP:6X@,&EN M(#!P="<^/&(^0V]M;6]N(%-H87)E6QE/3-$)TU! M4D=)3CHP:6X@,&EN(#!P="<^)FYB2`R M,#$R+"!T:&4@0V]M<&%N>2!R96-E:79E9"!C87-H(&]F("0Q,BPW,C`@:6X@ M97AC:&%N9V4@9F]R(#$X,2PV.3@@7!E.B!T97AT+VAT;6P[(&-H87)S970] M(G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T M<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@ M8VAA&5S/"]S=')O;F<^/"]T9#X- M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\'0^/"$M+65G>"TM/CQP('-T>6QE M/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^/&(^-2X\+V(^/"]P/B`\<"!S='EL M93TS1"=415A4+4E.1$5.5#HM,2XU<'0[($U!4D=)3CHP:6X@,&EN(#!P="<^ M/&(^26YC;VUE(%1A>&5S/"]B/CPO<#X@/'`@6QE/3-$)TU!4D=)3CHP:6X@ M,&EN(#!P="<^5&AE($-O;7!A;GD@:&%S("0Y,"PV.3<@;V8@;F5T(&]P97)A M=&EN9R!L;W-S97,@8V%R65A"!R871E(&]F(#,T)2!T;R!N M970@;&]S&5S+B!!2`R M.2P@,C`Q,BP@=&AE($-O;7!A;GD@:&%D(&YO('5N8V5R=&%I;B!T87@@<&]S M:71I;VYS+B`F;F)S<#L\+W`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`R.2P@/"]P/B`\<"!S='EL93TS M1"=415A4+4%,24=..F-E;G1E6QE/3-$)T)/4D1%4BU" M3U143TTZ(V5C93ED.#L@0D]21$52+4Q%1E0Z(V5C93ED.#L@4$%$1$E.1RU" M3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$ M24Y'+4Q%1E0Z,&EN.R!724142#HS+C6QE/3-$)T)/4D1%4BU"3U143TTZ(V5C93ED.#L@0D]21$52+4Q% M1E0Z(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/ M3$]2.G1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z,&EN.R!724142#HX,BXU M<'0[(%!!1$1)3D6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^3F5T(&QO&5S/"]P/CPO=&0^(#QT9"!W:61T:#TS1#(T('-T>6QE/3-$)T)/4D1%4BU" M3U143TTZ(V5C93ED.#L@0D]21$52+4Q%1E0Z(V5C93ED.#L@4$%$1$E.1RU" M3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0041$ M24Y'+4Q%1E0Z,&EN.R!724142#HP+C(U:6X[(%!!1$1)3D6QE/3-$)T)/4D1%4BU"3U143TTZ(V5C93ED.#L@0D]21$52 M+4Q%1E0Z(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$ M+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z,&EN.R!724142#HX M,7!T.R!0041$24Y'+5))1TA4.C!I;CL@0D]21$52+51/4#HC96-E.60X.R!" M3U)$15(M4DE'2%0Z(V5C93ED.#L@4$%$1$E.1RU43U`Z,&EN)R!V86QI9VX] M,T1B;W1T;VT^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ6QE M/3-$)T)/4D1%4BU"3U143TTZ8FQA8VL@,2XU<'0@6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^4W1A='5T M;W)Y(')A=&4\+W`^/"]T9#X@/'1D('=I9'1H/3-$,C0@6QE/3-$)T)/4D1%4BU"3U143TTZ M8FQA8VL@,2XU<'0@6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB6QE/3-$)T)/4D1% M4BU"3U143TTZ(V5C93ED.#L@0D]21$52+4Q%1E0Z(V5C93ED.#L@4$%$1$E. M1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$+4-/3$]2.G1R86YS<&%R96YT.R!0 M041$24Y'+4Q%1E0Z,&EN.R!724142#HS+C'!E8W1E9"!T87@@6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^5F%L=6%T:6]N(&%L;&]W86YC M93PO<#X\+W1D/B`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`R M.2P@,C`Q,B!A;F0@1F5B6QE/3-$)T)/4D1%4BU"3U143TTZ(V5C93ED.#L@0D]21$52 M+4Q%1E0Z(V5C93ED.#L@4$%$1$E.1RU"3U143TTZ,&EN.R!"04-+1U)/54Y$ M+4-/3$]2.G1R86YS<&%R96YT.R!0041$24Y'+4Q%1E0Z,&EN.R!724142#HQ M,2XR-7!T.R!0041$24Y'+5))1TA4.C!I;CL@0D]21$52+51/4#HC96-E.60X M.R!"3U)$15(M4DE'2%0Z(V5C93ED.#L@4$%$1$E.1RU43U`Z,&EN)SX\+W1D M/B`\=&0@=VED=&@],T0Y-B!S='EL93TS1"="3U)$15(M0D]45$]-.B-E8V4Y M9#@[($)/4D1%4BU,1494.B-E8V4Y9#@[(%!!1$1)3D6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB M6QE/3-$)T)/4D1%4BU" M3U143TTZ8FQA8VL@,7!T('-O;&ED.R!"3U)$15(M3$5&5#HC96-E.60X.R!0 M041$24Y'+4)/5%1/33HP:6X[($)!0TM'4D]53D0M0T],3U(Z=')A;G-P87)E M;G0[(%!!1$1)3D2`R.2P@/"]P/B`\<"!S='EL93TS1"=4 M15A4+4%,24=..F-E;G1E6QE/3-$)T)/4D1%4BU"3U143TTZ8FQA M8VL@,7!T('-O;&ED.R!"3U)$15(M3$5&5#HC96-E.60X.R!0041$24Y'+4)/ M5%1/33HP:6X[($)!0TM'4D]53D0M0T],3U(Z=')A;G-P87)E;G0[(%!!1$1) M3D6QE/3-$)U1%6%0M04Q)1TXZ8V5N M=&5R.R!-05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/D9E8G)U M87)Y(#(X+"`\+W`^(#QP('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!- M05)'24XZ,&EN(#!I;B`P<'0G(&%L:6=N/3-$8V5N=&5R/C(P,3$\+W`^(#QP M('-T>6QE/3-$)U1%6%0M04Q)1TXZ8V5N=&5R.R!-05)'24XZ,&EN(#!I;B`P M<'0G(&%L:6=N/3-$8V5N=&5R/B0\+W`^/"]T9#X\+W1R/B`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`N,C5P=#L@4$%$ M1$E.1RU224=(5#HP:6X[($)/4D1%4BU43U`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`P:6X@,'!T)SX\8CY3=6)S97%U96YT($5V96YT M6QE/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^)FYB M2P@=&AE($-O;7!A;GD@28C,30V.W,@8V]M;6]N('-T;V-K+CPO<#X@/'`@6QE M/3-$)TU!4D=)3CHP:6X@,&EN(#!P="<^26X@86-C;W)D86YC92!W:71H($%3 M0R`X-34M,3`@=&AE($-O;7!A;GD@:&%S(&%N86QY>F5D(&ET2`R.2P@,C`Q,B!T:')O=6=H M('1H92!D871E('1H97-E(&9I;F%N8VEA;"!S=&%T96UE;G1S('=E XML 17 R8.htm IDEA: XBRL DOCUMENT v2.4.0.6

Summary of Significant Accounting Policies
12 Months Ended

Feb. 29, 2012

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies
2.

Summary of Significant Accounting Policies

a)

Basis of Presentation

The financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“US GAAP”) and are expressed in U.S. dollars. The Company’s fiscal year end is February 28.

b)

Use of Estimates

The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions related to the deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected.

c)

Cash and cash equivalents

The Company considers all highly liquid instruments with a maturity of three months or less at the time of issuance to be cash equivalents.

d)

Basic and Diluted Net Loss per Share

The Company computes net loss per share in accordance with ASC 260, Earnings per Share. ASC 260 requires presentation of both basic and diluted earnings per share (“EPS”) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. Diluted EPS excludes all dilutive potential shares if their effect is anti dilutive. For the periods presented, there were no outstanding potential common stock equivalents and therefore basic and diluted earnings per share result in the same figure.

e)

Financial Instruments

Pursuant to ASC 820, Fair Value Measurements and Disclosures and ASC 825, Financial Instruments, an entity is required to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 establishes a fair value hierarchy based on the level of independent, objective evidence surrounding the inputs used to measure fair value. A financial instrument’s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the fair value measurement. ASC 820 prioritizes the inputs into three levels that may be used to measure fair value:

Level 1

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

Level 2

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

Level 3

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

The Company’s financial instruments consist principally of cash, accounts payable, and amounts due to related parties. Pursuant to ASC 820, the fair value of our cash is determined based on “Level 1” inputs, which consist of quoted prices in active markets for identical assets. We believe that the recorded values of all of our other financial instruments approximate their current fair values because of their nature and respective maturity dates or durations.

f)

Comprehensive Loss

ASC 220, Comprehensive Income, establishes standards for the reporting and display of comprehensive loss and its components in the financial statements. As of February 29, 2012, the Company has no items that represent a comprehensive loss and, therefore, has not included a schedule of comprehensive loss in the financial statements.

g)

Recent Accounting Pronouncements

The Company has implemented all new accounting pronouncements that are in effect. These pronouncements did not have any material impact on the financial statements unless otherwise disclosed, and the Company does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its financial position or results of operations.

h)

Income Taxes

Potential benefits of income tax losses are not recognized in the accounts until realization is more likely than not. The Company has adopted ASC 740 “Accounting for Income Taxes” as of its inception. Pursuant to ASC 740, the Company is required to compute tax asset benefits for net operating losses carried forward. The potential benefits of net operating losses have not been recognized in this financial statement because the Company cannot be assured it is more likely than not it will utilize the net operating losses carried forward in future years.

X

- Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18743-107790

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18854-107790

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 22

-Paragraph 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18861-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18726-107790

+ Details

Name: us-gaap_SignificantAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 18 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6

Balance Sheets (USD $)

Feb. 29, 2012

Feb. 28, 2011

ASSETS

Cash $ 12,386 $ 9,000

Total Assets 12,386 9,000

Current Liabilities

Accounts payable 55,472 5,000

Due to related parties 34,891 10,000

Total Liabilities 90,363 15,000

STOCKHOLDERS' DEFICIT

Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares 0 0

Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,181,698 and 5,000,000 common shares, respectively 5,182 5,000

Additional paid-in capital 7,538 (5,000)

Accumulated deficit during the development stage (90,697) (6,000)

Total Stockholders' Deficit (77,977) (6,000)

Total Liabilities and Stockholders' Deficit $ 12,386 $ 9,000

X

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AccountsPayableCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 31

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.30(a)(1))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_AdditionalPaidInCapital

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 12

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Topic 210

-SubTopic 10

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

-Section S99

-Name Accounting Standards Codification

-Publisher FASB

-Paragraph 1

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Concepts (CON)

-Number 6

-Paragraph 25

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 18

-Article 5

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.18)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Assets

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: us-gaap_AssetsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Cumulative net losses reported during the development stage.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 7

-Paragraph 11

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 210

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472335&loc=d3e37729-110921

+ Details

Name: us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19(a))

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(k)(1))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 19

-Subparagraph a

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 850

-SubTopic 10

-Section 50

-Paragraph 1

-Subparagraph (d)

-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph k

-Subparagraph 1

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 57

-Paragraph 2

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_DueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.19-26)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_Liabilities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all Liabilities and Stockholders' Equity items (or Partners' Capital, as applicable), including the portion of equity attributable to noncontrolling interests, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 32

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.32)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 7

-Section 03

-Paragraph 25

+ Details

Name: us-gaap_LiabilitiesAndStockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_LiabilitiesCurrentAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

+ Details

Name: us-gaap_PreferredStockValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A3

-Appendix A

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Details

Name: us-gaap_StockholdersEquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 19 R6.htm IDEA: XBRL DOCUMENT v2.4.0.6

Statements of Stockholders' Deficit (USD $)

Common Stock Shares

Common stock Par Value

USD ($)

Additional paid-in capital

USD ($)

Accumulated deficit

USD ($)

Total

USD ($)

Balance at Feb. 08, 2011 0 0 0 0 0

Issuance of founders shares 5,000,000 5,000 (5,000) 0 0

Net loss for the period $ 0 $ 0 $ (6,000) $ (6,000)

Balance at Feb. 28, 2011 5,000,000 5,000 (5,000) (6,000) (6,000)

Common stock issued for cash 181,698 182 12,538 0 12,720

Net loss for the year $ 0 $ 0 $ (84,697) $ (84,697)

Balance at Feb. 29, 2012 5,181,698 5,182 7,538 (90,697) (77,977)

X

- Definition

Issuance of founders shares during the period

+ References

No definition available.

+ Details

Name: fil_IssuanceOfFoundersShares

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

No definition available.

+ Details

Name: fil_NetLossForThePeriod

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

No definition available.

+ Details

Name: fil_NetLossForTheYear

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Number of shares issued and outstanding as of the balance sheet date.

+ References

No definition available.

+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Number of new stock issued during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30

-Article 5

+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 20 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.1.0.1 * */ var moreDialog = null; var Show = { Default:'raw', more:function( obj ){ var bClosed = false; if( moreDialog != null ) { try { bClosed = moreDialog.closed; } catch(e) { //Per article at http://support.microsoft.com/kb/244375 there is a problem with the WebBrowser control // that somtimes causes it to throw when checking the closed property on a child window that has been //closed. So if the exception occurs we assume the window is closed and move on from there. bClosed = true; } if( !bClosed ){ moreDialog.close(); } } obj = obj.parentNode.getElementsByTagName( 'pre' )[0]; var hasHtmlTag = false; var objHtml = ''; var raw = ''; //Check for raw HTML var nodes = obj.getElementsByTagName( '*' ); if( nodes.length ){ objHtml = obj.innerHTML; }else{ if( obj.innerText ){ raw = obj.innerText; }else{ raw = obj.textContent; } var matches = raw.match( /<\/?[a-zA-Z]{1}\w*[^>]*>/g ); if( matches && matches.length ){ objHtml = raw; //If there is an html node it will be 1st or 2nd, // but we can check a little further. var n = Math.min( 5, matches.length ); for( var i = 0; i < n; i++ ){ var el = matches[ i ].toString().toLowerCase(); if( el.indexOf( '= 0 ){ hasHtmlTag = true; break; } } } } if( objHtml.length ){ var html = ''; if( hasHtmlTag ){ html = objHtml; }else{ html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ objHtml + "\n"+''+ "\n"+''; } moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write( html ); moreDialog.document.close(); if( !hasHtmlTag ){ moreDialog.document.body.style.margin = '0.5em'; } } else { //default view logic var lines = raw.split( "\n" ); var longest = 0; if( lines.length > 0 ){ for( var p = 0; p < lines.length; p++ ){ longest = Math.max( longest, lines[p].length ); } } //Decide on the default view this.Default = longest < 120 ? 'raw' : 'formatted'; //Build formatted view var text = raw.split( "\n\n" ) >= raw.split( "\r\n\r\n" ) ? raw.split( "\n\n" ) : raw.split( "\r\n\r\n" ) ; var formatted = ''; if( text.length > 0 ){ if( text.length == 1 ){ text = raw.split( "\n" ) >= raw.split( "\r\n" ) ? raw.split( "\n" ) : raw.split( "\r\n" ) ; formatted = "
"+ text.join( "

\n" ) +"
"; }else{ for( var p = 0; p < text.length; p++ ){ formatted += "
" + text[p] + "
\n"; } } }else{ formatted = '
' + raw + '
'; } html = ''+ "\n"+''+ "\n"+' Report Preview Details'+ "\n"+' '+ "\n"+''+ "\n"+''+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+' '+ "\n"+'
'+ "\n"+' formatted: '+ ( this.Default == 'raw' ? 'as Filed' : 'with Text Wrapped' ) +''+ "\n"+'
'+ "\n"+'
'+formatted+'
'+ "\n"+'
'+ "\n"+'
'+raw+'
'+ "\n"+'
'+ "\n"+''+ "\n"+''; moreDialog = window.open("","More","width=700,height=650,status=0,resizable=yes,menubar=no,toolbar=no,scrollbars=yes"); moreDialog.document.write(html); moreDialog.document.close(); this.toggle( moreDialog ); } moreDialog.document.title = 'Report Preview Details'; }, toggle:function( win, domLink ){ var domId = this.Default; var doc = win.document; var domEl = doc.getElementById( domId ); domEl.style.display = 'block'; this.Default = domId == 'raw' ? 'formatted' : 'raw'; if( domLink ){ domLink.innerHTML = this.Default == 'raw' ? 'with Text Wrapped' : 'as Filed'; } var domElOpposite = doc.getElementById( this.Default ); domElOpposite.style.display = 'none'; }, LastAR : null, showAR : function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }, toggleNext : function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }, hideAR : function(){ Show.LastAR.style.display = 'none'; } } XML 21 R7.htm IDEA: XBRL DOCUMENT v2.4.0.6

Nature of Operations and Continuance of Business
12 Months Ended

Feb. 29, 2012

Nature of Operations and Continuance of Business

Nature of Operations and Continuance of Business
1.

Nature of Operations and Continuance of Business

Pharma Investing News, Inc. (the “Company”) was incorporated in the State of Nevada on February 8, 2011. The Company is a Development Stage Company, as defined by Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 915, Development Stage Entities.

Going Concern

These financial statements have been prepared on a going concern basis, which implies that the Company will continue to realize its assets and discharge its liabilities in the normal course of business. As of February 29, 2012, the Company has not recognized any revenue, and has a working capital deficit and an accumulated deficit of $90,697. The continuation of the Company as a going concern is dependent upon the continued financial support from its management, and its ability to identify future investment opportunities and obtain the necessary debt or equity financing, and generating profitable operations from the Company’s future operations. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern. These financial statements do not include any adjustments to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

X

- Definition

The entire disclosure for the nature of an entity's business, the major products or services it sells or provides and its principal markets, including the locations of those markets. If the entity operates in more than one business, the disclosure also indicates the relative importance of its operations in each business and the basis for the determination (for example, assets, revenues, or earnings).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Name Statement of Position (SOP)

-Publisher AICPA

-Number 94-6

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6003-108592

+ Details

Name: us-gaap_NatureOfOperations

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 22 R3.htm IDEA: XBRL DOCUMENT v2.4.0.6

Balance Sheets Parentheticals (USD $)

Feb. 29, 2012

Feb. 28, 2011

Preferred Stock, par value $ 0.001 $ 0.001

Preferred Stock, shares authorized 10,000,000 10,000,000

Common Stock, par value $ 0.001 $ 0.001

Common Stock, shares authorized 290,000,000 290,000,000

Common Stock, shares issued 5,181,698 5,000,000

Common Stock, shares outstanding 5,181,698 5,000,000

X

- Definition

Face amount or stated value of common stock per share; generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 4

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_CommonStockSharesIssued

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Total number of shares of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares represent the ownership interest of the common shareholders. Shares outstanding equals shares issued minus shares held in treasury and other adjustments, if any.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 30

-Article 5

+ Details

Name: us-gaap_CommonStockSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Face amount or stated value per share of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer); generally not indicative of the fair market value per share.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Name: us-gaap_PreferredStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 02

-Paragraph 29

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.28)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

+ Details

Name: us-gaap_PreferredStockSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

XML 23 R1.htm IDEA: XBRL DOCUMENT v2.4.0.6

Document and Entity Information (USD $)
12 Months Ended

Feb. 29, 2012

Jun. 06, 2012

Document and Entity Information

Entity Registrant Name PHARMA INVESTING NEWS, INC.

Document Type 10-K

Document Period End Date Feb. 29, 2012

Amendment Flag false

Entity Central Index Key 0001520047

Current Fiscal Year End Date --02-28

Entity Common Stock, Shares Outstanding 5,361,015

Entity Filer Category Smaller Reporting Company

Entity Current Reporting Status Yes

Entity Voluntary Filers No

Entity Well-known Seasoned Issuer No

Document Fiscal Year Focus 2013

Document Fiscal Period Focus FY

Entity Public Float $ 0

X

- Definition

If the value is true, then the document as an amendment to previously-filed/accepted document.

+ References

No definition available.

+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition

End date of current fiscal year in the format --MM-DD.

+ References

No definition available.

+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition

This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

+ References

No definition available.

+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition

The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.

+ References

No definition available.

+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition

The type of document being provided (such as 10-K, 10-Q, N-1A, etc). The document type is limited to the same value as the supporting SEC submission type, minus any "/A" suffix. The acceptable values are as follows: S-1, S-3, S-4, S-11, F-1, F-3, F-4, F-9, F-10, 6-K, 8-K, 10, 10-K, 10-Q, 20-F, 40-F, N-1A, 485BPOS, 497, NCSR, N-CSR, N-CSRS, N-Q, 10-KT, 10-QT, 20-FT, POS AM and Other.

+ References

No definition available.

+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate number of shares outstanding of each of registrant's classes of common stock, as of latest practicable date. Where multiple classes exist define each class by adding class of stock items such as Common Class A [Member], Common Class B [Member] onto the Instrument [Domain] of the Entity Listings, Instrument

+ References

No definition available.

+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition

Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, or (4) Smaller Reporting Company. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

+ References

No definition available.

+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition

State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.

+ References

No definition available.

+ Details

Name: dei_EntityPublicFloat

Namespace Prefix: dei_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation 12B

-Number 240

-Section 12b

-Subsection 1

+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

+ References

No definition available.

+ Details

Name: dei_EntityVoluntaryFilers

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition

Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.

+ References

No definition available.

+ Details

Name: dei_EntityWellKnownSeasonedIssuer

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Details

Name: fil_DocumentAndEntityInformationAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 24 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6

Statements of Operations (USD $)
1 Months Ended 12 Months Ended

Feb. 28, 2011

Feb. 29, 2012

Feb. 29, 2012

Revenues $ 0 $ 0 $ 0

Operating Expenses

Consulting fees 0 5,000 5,000

General and administrative 1,000 5,424 6,424

Professional fees 5,000 74,273 79,273

Total Operating Expenses 6,000 84,697 90,697

Net Loss $ (6,000) $ (84,697) $ (90,697)

Net Loss per Share - Basic and Diluted $ 0.00 $ (0.02)

Weighted Average Shares Outstanding - Basic and Diluted 5,000,000 5,012,282

X

- Definition

The charge during the reporting period towards consultation charges

+ References

No definition available.

+ Details

Name: fil_ConsultingFees

Namespace Prefix: fil_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The average number of shares or units issued and outstanding that are used in calculating basic and diluted EPS.

+ References

No definition available.

+ Details

Name: fil_WeightedAverageSharesOutstandingBasicAndDiluted

Namespace Prefix: fil_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

No definition available.

+ Details

Name: us-gaap_EarningsPerShareBasicAndDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.4)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

+ References

No definition available.

+ Details

Name: us-gaap_OperatingExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_OperatingExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.6-07.2(a),(b),(c),(d))

-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 946

-SubTopic 225

-Section 45

-Paragraph 3

-Subparagraph (k)

-URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849

+ Details

Name: us-gaap_ProfessionalFees

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4J

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591551-111686

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A1, A4, A5

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph c(1)

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1A

-Subparagraph (a),(c)

-URI http://asc.fasb.org/extlink&oid=6921930&loc=SL4573702-111684

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 55

-Paragraph 4K

-URI http://asc.fasb.org/extlink&oid=6922042&loc=SL4591552-111686

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 5

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 45

-Paragraph 19

-URI http://asc.fasb.org/extlink&oid=6921628&loc=SL4569616-111683

+ Details

Name: us-gaap_ProfitLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

Aggregate revenue recognized during the period (derived from goods sold, services rendered, insurance premiums, or other activities that constitute an entity's earning process). For financial services companies, also includes investment and interest income, and sales and trading gains.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 1

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

+ Details

Name: us-gaap_Revenues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

XML 25 R12.htm IDEA: XBRL DOCUMENT v2.4.0.6

Subsequent Events
12 Months Ended

Feb. 29, 2012

Subsequent Events

Subsequent Events
6.

Subsequent Events

During March through May, the Company received cash of $12,550 in exchange for 179,317 shares of the Company’s common stock.

In accordance with ASC 855-10 the Company has analyzed its operations subsequent from February 29, 2012 through the date these financial statements were issued, and has determined there are no material subsequent events to disclose in these financial statements.

X

- Details

Name: us-gaap_SubsequentEventsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

+ References

No definition available.

+ Details

Name: us-gaap_SubsequentEventsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 26 R11.htm IDEA: XBRL DOCUMENT v2.4.0.6

Income Taxes
12 Months Ended

Feb. 29, 2012

Income Taxes

Income Taxes
5.

Income Taxes

The Company has $90,697 of net operating losses carried forward to offset taxable income in future years which expire commencing in fiscal 2031. The income tax benefit differs from the amount computed by applying the US federal income tax rate of 34% to net loss before income taxes. As at February 29, 2012, the Company had no uncertain tax positions.

February 29,

2012

$

February 28,

2011

$

Net loss before taxes

(84,697)

(6,000)

Statutory rate

34%

34%

Computed expected tax recovery

28,797

2,040

Valuation allowance

(28,797)

(2,040)

Income tax provision

–

–

The significant components of deferred income tax assets and liabilities at February 29, 2012 and February 28, 2011 are as follows:

February 29,

2012

$

February 28,

2011

$

Net operating loss carried forward

30,837

2,040

Valuation allowance

(30,837)

(2,040)

Net deferred income tax asset

–

–

X

- Details

Name: fil_IncomeTaxesAbstract

Namespace Prefix: fil_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32537-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 136, 172

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 109

-Paragraph 43, 44, 45, 46, 47, 48, 49

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph h

-Article 4

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32559-109319

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 9

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 15

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32718-109319

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(h))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

+ Details

Name: us-gaap_IncomeTaxDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 27 R5.htm IDEA: XBRL DOCUMENT v2.4.0.6

Statements of Cash Flows (USD $)
1 Months Ended 12 Months Ended

Feb. 28, 2011

Feb. 29, 2012

Feb. 29, 2012

Operating Activities

Net loss for the period $ (6,000) $ (84,697) $ (90,697)

Changes in operating assets and liabilities:

Accounts payable 5,000 50,472 55,472

Expenses paid by related parties 0 4,817 4,817

Net Cash Used In Operating Activities (1,000) (29,408) (30,408)

Financing Activities

Proceeds from related party 10,000 20,074 30,074

Proceeds from issuance of common shares 0 12,720 12,720

Net Cash Provided by Financing Activities 10,000 32,794 42,794

Change in Cash 9,000 3,386 12,386

Cash - Beginning of Period 9,000

Cash - End of Period 9,000 12,386 12,386

Supplemental Disclosures

Interest paid 0 0 0

Income tax paid $ 0 $ 0 $ 0

X

- Definition

Includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the Entity may deposit additional funds at any time and also effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Compensating balance arrangements that do not legally restrict the withdrawal or usage of cash amounts may be reported as Cash and Cash Equivalents, while legally restricted deposits held as compensating balances against borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits are not generally reported as cash and cash equivalents. Includes cash and cash equivalents associated with the entity's continuing operations. Excludes cash and cash equivalents associated with the disposal group (and discontinued operation).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.1)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 1

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7

-Footnote 1

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3044-108585

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 8, 9

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section 45

-Paragraph 1

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6361293&loc=d3e6676-107765

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash

-URI http://asc.fasb.org/extlink&oid=6506951

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 7, 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Cash Equivalents

-URI http://asc.fasb.org/extlink&oid=6507016

+ Details

Name: us-gaap_CashAndCashEquivalentsAtCarryingValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition

The increase (decrease) during the reporting period in cash and cash equivalents. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

+ Details

Name: us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 27

-Subparagraph f

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_IncomeTaxesPaidNet

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInAccountsPayable

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The amount of cash paid for interest during the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 29

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-Subparagraph (e)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4297-108586

+ Details

Name: us-gaap_InterestPaid

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The net cash inflow or outflow from financing activity for the period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 26

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3574-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The net cash from (used in) all of the entity's operating activities, including those of discontinued operations, of the reporting entity. Operating activities generally involve producing and delivering goods and providing services. Operating activity cash flows include transactions, adjustments, and changes in value that are not defined as investing or financing activities. While for technical reasons this element has no balance attribute, the default assumption is a debit balance consistent with its label.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 24

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3521-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 25

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3536-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 26

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

+ Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.22)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 28

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.18)

-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 260

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 220

-SubTopic 10

-Section 45

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6920043&loc=d3e565-108580

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph A7

-Appendix A

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 130

-Paragraph 10, 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Other Comprehensive Income

-URI http://asc.fasb.org/extlink&oid=6519514

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 51

-Paragraph 38

-Subparagraph d

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Emerging Issues Task Force (EITF)

-Number 87-21

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Net Income

-URI http://asc.fasb.org/extlink&oid=6518256

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 944

-SubTopic 225

-Section S99

-Paragraph 1

-Subparagraph (SX 210.7-04.19)

-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 5

-Section 03

-Paragraph 19

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 28, 29, 30

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Paragraph 20

-Article 9

+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition

The cash inflow from the additional capital contribution to the entity.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (a)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph a

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromIssuanceOfCommonStock

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition

The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 230

-SubTopic 10

-Section 45

-Paragraph 14

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3255-108585

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 18

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 95

-Paragraph 19

-Subparagraph b

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Financing Activities

-URI http://asc.fasb.org/extlink&oid=6513228

+ Details

Name: us-gaap_ProceedsFromRelatedPartyDebt

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Details

Name: us-gaap_SupplementalCashFlowInformationAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 28 R10.htm IDEA: XBRL DOCUMENT v2.4.0.6

Common Shares
12 Months Ended

Feb. 29, 2012

Common Shares

Common Shares
4.

Common Shares

During January and February 2012, the Company received cash of $12,720 in exchange for 181,698 shares of the Company’s common stock.

X

- Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 129

-Paragraph 2, 3, 4, 5, 6, 7, 8

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 5

-Paragraph 15

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Article 4

-Section 08

-Paragraph d

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Research Bulletin (ARB)

-Number 43

-Chapter 1

-Section B

-Paragraph 7, 11A

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 20: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 21: http://www.xbrl.org/2003/role/presentationRef

-Publisher AICPA

-Name Accounting Principles Board Opinion (APB)

-Number 12

-Paragraph 10

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 22: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 23: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

+ Details

Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 29 FilingSummary.xml IDEA: XBRL DOCUMENT 2.4.0.6 Html 32 60 1 false 5 0 false 3 false false R1.htm 000010 - Document - Document and Entity Information Sheet http://www.pharmainvestingnews.com/20120229/role/idr_DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 000020 - Statement - Balance Sheets Sheet http://www.pharmainvestingnews.com/20120229/role/idr_BalanceSheets Balance Sheets false false R3.htm 000030 - Statement - Balance Sheets Parentheticals Sheet http://www.pharmainvestingnews.com/20120229/role/idr_BalanceSheetsParentheticals Balance Sheets Parentheticals false false R4.htm 000040 - Statement - Statements of Operations Sheet http://www.pharmainvestingnews.com/20120229/role/idr_StatementsOfOperations Statements of Operations false false R5.htm 000050 - Statement - Statements of Cash Flows Sheet http://www.pharmainvestingnews.com/20120229/role/idr_StatementsOfCashFlows Statements of Cash Flows false false R6.htm 000055 - Statement - Statements of Stockholders' Deficit Sheet http://www.pharmainvestingnews.com/20120229/role/idr_StatementsOfStockholdersDeficit Statements of Stockholders' Deficit false false R7.htm 000060 - Disclosure - Nature of Operations and Continuance of Business Sheet http://www.pharmainvestingnews.com/20120229/role/idr_DisclosureNatureOfOperationsAndContinuanceOfBusiness Nature of Operations and Continuance of Business false false R8.htm 000070 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.pharmainvestingnews.com/20120229/role/idr_DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R9.htm 000080 - Disclosure - Related Party Transactions Sheet http://www.pharmainvestingnews.com/20120229/role/idr_DisclosureRelatedPartyTransactions Related Party Transactions false false R10.htm 000090 - Disclosure - Common Shares Sheet http://www.pharmainvestingnews.com/20120229/role/idr_DisclosureCommonShares Common Shares false false R11.htm 000100 - Disclosure - Income Taxes Sheet http://www.pharmainvestingnews.com/20120229/role/idr_DisclosureIncomeTaxes Income Taxes false false R12.htm 000110 - Disclosure - Subsequent Events Sheet http://www.pharmainvestingnews.com/20120229/role/idr_DisclosureSubsequentEvents Subsequent Events false false All Reports Book All Reports Process Flow-Through: 000020 - Statement - Balance Sheets Process Flow-Through: Removing column 'Feb. 07, 2011' Process Flow-Through: 000030 - Statement - Balance Sheets Parentheticals Process Flow-Through: 000040 - Statement - Statements of Operations Process Flow-Through: 000050 - Statement - Statements of Cash Flows pini-20120229.xml pini-20120229.xsd pini-20120229_cal.xml pini-20120229_def.xml pini-20120229_lab.xml pini-20120229_pre.xml true true

Balance Sheets (USD $)	Feb. 29, 2012	Feb. 28, 2011
ASSETS
Cash	$ 12,386	$ 9,000
Total Assets	12,386	9,000
Current Liabilities
Accounts payable	55,472	5,000
Due to related parties	34,891	10,000
Total Liabilities	90,363	15,000
STOCKHOLDERS' DEFICIT
Preferred Stock Authorized: 10,000,000 preferred shares with a par value of $0.001 per share Issued and outstanding: nil preferred shares	0	0
Common Stock Authorized: 290,000,000 common shares with a par value of $0.001 per share Issued and outstanding: 5,181,698 and 5,000,000 common shares, respectively	5,182	5,000
Additional paid-in capital	7,538	(5,000)
Accumulated deficit during the development stage	(90,697)	(6,000)
Total Stockholders' Deficit	(77,977)	(6,000)
Total Liabilities and Stockholders' Deficit	$ 12,386	$ 9,000

Statements of Stockholders' Deficit (USD $)	Common Stock Shares	Common stock Par Value USD ($)	Additional paid-in capital USD ($)	Accumulated deficit USD ($)	Total USD ($)
Balance at Feb. 08, 2011	0	0	0	0	0
Issuance of founders shares	5,000,000	5,000	(5,000)	0	0
Net loss for the period		$ 0	$ 0	$ (6,000)	$ (6,000)
Balance at Feb. 28, 2011	5,000,000	5,000	(5,000)	(6,000)	(6,000)
Common stock issued for cash	181,698	182	12,538	0	12,720
Net loss for the year		$ 0	$ 0	$ (84,697)	$ (84,697)
Balance at Feb. 29, 2012	5,181,698	5,182	7,538	(90,697)	(77,977)

Balance Sheets Parentheticals (USD $)	Feb. 29, 2012	Feb. 28, 2011
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	290,000,000	290,000,000
Common Stock, shares issued	5,181,698	5,000,000
Common Stock, shares outstanding	5,181,698	5,000,000

Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Feb. 29, 2012	Jun. 06, 2012
Document and Entity Information
Entity Registrant Name	PHARMA INVESTING NEWS, INC.
Document Type	10-K
Document Period End Date	Feb. 29, 2012
Amendment Flag	false
Entity Central Index Key	0001520047
Current Fiscal Year End Date	--02-28
Entity Common Stock, Shares Outstanding		5,361,015
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	FY
Entity Public Float	$ 0

Statements of Operations (USD $)	1 Months Ended	12 Months Ended
Statements of Operations (USD $)	Feb. 28, 2011	Feb. 29, 2012	Feb. 29, 2012
Revenues	$ 0	$ 0	$ 0
Operating Expenses
Consulting fees	0	5,000	5,000
General and administrative	1,000	5,424	6,424
Professional fees	5,000	74,273	79,273
Total Operating Expenses	6,000	84,697	90,697
Net Loss	$ (6,000)	$ (84,697)	$ (90,697)
Net Loss per Share - Basic and Diluted	$ 0.00	$ (0.02)
Weighted Average Shares Outstanding - Basic and Diluted	5,000,000	5,012,282

Statements of Cash Flows (USD $)	1 Months Ended	12 Months Ended
Statements of Cash Flows (USD $)	Feb. 28, 2011	Feb. 29, 2012	Feb. 29, 2012
Operating Activities
Net loss for the period	$ (6,000)	$ (84,697)	$ (90,697)
Changes in operating assets and liabilities:
Accounts payable	5,000	50,472	55,472
Expenses paid by related parties	0	4,817	4,817
Net Cash Used In Operating Activities	(1,000)	(29,408)	(30,408)
Financing Activities
Proceeds from related party	10,000	20,074	30,074
Proceeds from issuance of common shares	0	12,720	12,720
Net Cash Provided by Financing Activities	10,000	32,794	42,794
Change in Cash	9,000	3,386	12,386
Cash - Beginning of Period		9,000
Cash - End of Period	9,000	12,386	12,386
Supplemental Disclosures
Interest paid	0	0	0
Income tax paid	$ 0	$ 0	$ 0